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“Biomaterials science is the physical and biological study of materials and their 
interaction with the biological environment.“ 
 
Ratner BD, Hoffmann AS, Schoen FJ, Lemons JE. Biomaterials Science. An Introduction to Materials in 
Medicine. 2nd ed. London: Academic Press, 1996. 
 
 
“Give me a chance to create fever and I will cure any disease” 
 
Parménides, 500 BC. 
 
 
“Quae medicamenta non sanat; ferrum sanat. Quae ferrum non sanat; ignis sanat. 
Quae vero ignis non sanat; insanabilia reportari oportet”  
 
(Those diseases which medicines do not cure, the knife cures; those which the knife 
cannot cure, fire cures; and those which fire cannot cure, are to be reckoned wholly 
incurable.) 
 
Hippocrates, 460-370 BC. 
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Abstract 
 
The use of biomaterials is widely generalized due, in part, to the development of 
new technologies and methodologies as a result of synergies and interactions between 
different scientific fields such as medicine, biology and engineering, and its 
consequent impact, qualitatively and quantitatively, in the options that different 
materials can offer. 
The swift development of biomaterials science, over the last few years, has 
enabled and enhanced its use in several medical specialties. In oncology, the 
biomaterials have been object of an increasing use as a medical treatment device, 
acting as a vehicle, and serving for the subsequent release, of certain drugs in 
chemotherapy, acting in the heat production in hyperthermia and, after treatment, in 
the subsequent rehabilitation through tissue regeneration and implants.	  
The present study, based on the concept of hyperthermia in the treatment of 
cancer, had as its objective the development of a material, denominated as 
Ferrimagnetic Cement (FC), that allows focusing the heat, only, in the FC injected 
into the tumour. This procedure aims to avoid damaging adjacent healthy tissues in an 
attempt to overcome the hyperthermia techniques limitations.	  
The in vitro experimentation, as the initial step of this investigation, consisted in 
the determination of the FC injectability, the evaluation of its interaction with a 
simulated biological medium through the physical-chemical characterization of its 
surface and the determination of the FC capacity to generate heat when exposed to a 
magnetic field. 
The in vivo biocompatibility studies were performed through the intramuscular 
implantation of FC in the animal model, using the histological analysis to assess the 
biological response. 
Based on the obtained results, FC demonstrated that has the proper conditions to 
be used in Highly Focalized Thermotherapy (HFT), which consists in the direct 
injection of the material in the solid tumour and in the heat production when exposed 
to a magnetic field, constituting this procedure the methodology proposed for this 
study.	  
With the purpose to evaluate the efficiency of the described methodology for 
the tumour destruction using FC, it was carried out in this study, the injection of FC in 
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the tumour (melanoma mouse model), the localization of the material through the 
radiographic image, and the control of temperature of the animal and the tumour 
using a thermal camera.	  
As result of the fact that the structure of FC stabilize in the tumour, its iron 
content is not transported to unwanted sites, in particular organs, allowing the 
repetition of treatments, through successive exposures to the magnetic field, without 
resorting to new injections of FC and, consequently, avoiding adverse effects to the 
body.	  
The significant inhibition of the normal tumour growth seems to be due to the 
destruction of tumour cells by necrosis or apoptosis in response to the temperature 
increase in the tumour.	  
The studied methodology could be used in the solid tumours treatment, since it 
is a minimally invasive technique and it can reduce the tumour growth. However, 
there are some unclear questions or not evaluated in the present study that should be 
developed in future investigations, to valorise its clinical application.  
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Resumo 
 
A utilização de biomateriais encontra-se amplamente generalizada devido, em 
parte, ao desenvolvimento de novas tecnologias e metodologias resultantes de 
sinergias e interações entre diferentes áreas científicas tais como a medicina, a 
biologia e a engenharia, e o seu consequente impacto, qualitativo e quantitativo, nas 
opções que os diferentes materiais oferecem. 
O acentuado desenvolvimento da ciência de biomateriais, ao longo dos últimos 
anos, tem permitido e potenciado a sua utilização em diversas especialidades da 
medicina. Em oncologia, os biomateriais têm sido objecto de crescente utilização 
como dispositivos médicos de tratamento, atuando como veículo, e servindo para a 
posterior libertação, de determinados fármacos em quimioterapia, na produção de 
calor em hipertermia e, após o tratamento, na consequente reabilitação através da 
regeneração de tecidos ou implantes. 
O presente estudo, baseando-se no conceito de hipertermia no tratamento do 
cancro, teve o objetivo de desenvolver um material, denominado Cimento 
Ferrimagnético (FC), que permita focalizar o calor, apenas, no FC injetado no interior 
do tumor. Este procedimento visa não danificar os tecidos sãos adjacentes, na 
tentativa de ultrapassar as limitações das técnicas de hipertermia existentes. 
A experimentação in vitro, sendo o passo inicial desta investigação, consistiu 
em determinar a injetabilidade de FC, avaliar a sua interação com um meio biológico 
simulado através da caracterização físico-química da sua superfície e determinar a 
capacidade de FC para gerar calor quando exposto a um campo magnético. 
Os estudos de biocompatibilidade in vivo foram realizados através da 
implantação intramuscular de FC em modelo animal, tendo-se recorrido à análise 
histológica para efetuar a consequente avaliação da resposta biológica. 
Com base nos resultados obtidos, FC demonstrou ter condições para ser 
utilizado em Termoterapia Altamente Focalizada (TAF) no tratamento de tumores 
sólidos. Esta técnica consiste na injeção direta do material no tumor sólido e na 
produção de calor quando exposto a um campo magnético, constituindo este 
procedimento a metodologia preconizada para este estudo. 
Com o propósito de avaliar a eficiência da metodologia descrita para a 
destruição do tumor utilizando FC, procedeu-se à sua injeção no tumor (modelo de 
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melanoma em ratinho), à sua localização e distribuição no tumor, através de imagem 
radiográfica e ao controlo da temperatura, do animal e do tumor, recorrendo a uma 
câmara térmica. 
Em resultado de a estrutura de FC estabilizar no tumor, o seu conteúdo de ferro 
não é transportado para locais indesejados, nomeadamente órgãos, possibilitando a 
repetição de tratamentos, por meio de sucessivas exposições ao campo magnético, 
sem recorrer a novas injecções de FC e, consequentemente, evitando efeitos adversos 
ao organismo. 
A significativa diminuição do crescimento normal do tumor, parece ser 
consequência da destruição de células tumorais por necrose e apoptose, como resposta 
ao aumento da temperatura no tumor. 
A metodologia estudada poderá ser utilizada no tratamento de tumores sólidos, 
uma vez que é uma técnica minimamente invasiva e que reduz o crescimento do 
tumor. Contudo, há algumas questões que não ficaram esclarecidas, ou que não foram 
avaliadas no presente estudo e que deverão ser desenvolvidas em futuras 
investigações, de forma a valorizar a sua aplicação clínica. 
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Context and study objectives 
 
The present investigation work was based in the context of the biomaterial 
science and it’s affectation to a new method developed for the treatment of solid 
tumours using hyperthermia.  
Hyperthermia, in the tumour treatment, is based on the well-established concept 
that heat has selective lethal effects on tumour tissues (1). Nowadays, many 
techniques are available to produce hyperthermia, but they are generally limited by 
the inability to selective target the tumour cells, with subsequent risk of affecting 
adjacent healthy tissues (1, 2, 3). In an attempt to solve this limitation, a new 
hyperthermia technique was developed, the Highly Focalized Thermotherapy (HFT). 
This new methodology is based on the concept of the Magnetically Mediated 
Hyperthermia (MMH) (4). The technique consists in the direct injection of an 
experimental material, the Ferrimagnetic Cement (FC) within the tumour and then the 
exposition to a high frequency magnetic field (HFMF). The aim is to increase the 
tumour temperature, based on the principle that a magnetic particle can generate heat, 
under a HFMF. Heat is than dissipated throughout the tumour tissues. With this 
approach we pretend to localize the heat in the tumour region, to the intended 
temperature, without damaging normal tissue. 
Once FC was developed to be used in direct contact with the organism, it must 
be framed in the biomaterials science parameters. The biomaterials science is directed 
to the properties and applications of materials that are used in contact with biological 
systems (5). It is a multidisciplinary science and this was demonstrated in the present 
investigation by the collaboration with several Laboratory’s and Institutions, with 
different approaches. 
 
The objectives of the present study were: 
 
1. Evaluation of the biological behaviour of FC.  
Initial in vitro studies were performed to: 
a) the determination of FC injectability (Biomaterials Laboratory, Faculdade de 
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Medicina Dentária, Universidade do Porto - FMDUP); 
b) the evaluation of FC capability to generate heat when exposed to a HFMF 
(Metallurgy and Materials Department, Faculdade de Engenharia, Universidade do 
Porto - FEUP); 
c) the characterization of FC surface morphology and qualitative and semi-
quantitative analysis through the Scanning Electron Microscopy (SEM), the Energy 
Dispersion Spectroscopy (EDS) and the X-ray diffraction (XRD) after a SBF 
immersion in different periods of time (Centro de Estudos de Materiais, Universidade 
do Porto - CEMUP). 
The subsequent in vivo studies, were realized through the: 
a) FC intramuscular implantation in Wister rat (Experimental Surgery 
Laboratory, FMDUP); 
b) histological analyses (Haematoxylin and Eosin - HE) of the samples obtained 
with different implantation periods of time (Pathology Laboratory, Instituto de 
Ciências Biomédicas Abel Salazar, Universidade do Porto - ICBAS). 
 
2. The HFT application with FC and the evaluation of the treatment effectiveness 
in a melanoma mouse model. 
In vivo studies were performed: 
a) the melanoma mouse model induction through the subcutaneous injection of 
B16F10 cells (Pharmacology and Cell Biocompatibility Laboratory, FMDUP); 
b) the FC injection within the tumour (Experimental Surgery Laboratory, 
FMDUP); 
c) the determination of FC distribution by radiographic images (Imagiology 
Department, FMDUP); 
d) the animal exposition to the HFMF (Metallurgy and Materials Department, 
FEUP); 
e) the temperature monitoring with a thermographic camera (Labiomep, FEUP).  
f) the FC biological behaviour evaluation by the characterization of its surface 
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morphology and qualitative and semi-quantitative analysis through the SEM and EDS 
(CEMUP); 
g) the determination of the iron content in vital organs to evaluate the eventual 
migration of the FC ferromagnetic particles (Pathology Laboratory, ICBAS).  
h) the evaluation of the cells destruction mechanism, through the histological 
analyse  by haematoxylin and eosin (HE) and immunohistochemical (IHC) staining of 
the tumour, at the end of the HFT treatment (Pathology Laboratory, ICBAS). 
The obtained results were discussed and it was proposed the continuity of this 
investigation, with some suggestions and strategies to future studies based in the HFT 
potential for the solid tumours treatment. 
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1.1 – Biomaterials Science 
 
Historical Development 
The use of materials to specific applications, with a relatively acceptant degree 
of adaptation, is described in the remote medical treaty. A detailed description of 
materials applications in the oriental medicine extends back to time, 2500 years ago. 
The Egyptians developed sophisticated implants, like the gold used in dentistry, as 
well as the Greeks, the Romans and, in the American continent, the Inc and the Aztec 
(5, 6). For instance, the Etruscans learned to substitute missing teeth with bridges 
made from artificial teeth carved from the bones of oxen, and in the 17th century a 
piece of dog skull was successfully transplanted into the damaged skull of a Dutch 
duke. The Chinese recorded the first use of dental amalgam to repair decayed teeth in 
the year 659 AD, and the pre-Columbian civilizations used gold sheets to heal cranial 
cavities following trepanation. However, many other implantations failed as a result 
of infection or lack of knowledge about toxicity of the selected materials (7). 
The Biomaterials Science development begin in the lately XX century as a 
response of the palliative treatments needs (Figure 1). It is defined as a 
multidisciplinary science with a parallel development with advanced materials, 
initially designed for other application than the human organism (6). Figure 2 is a 
schematic board of the disciplines involved in biomaterials science and the evolution 
of the first idea from a need, to the medical device final manufacturing (5). 
 
Figure 1 - Historical development of the biomaterials application. The past, the present and future 
expectations (6). 
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Figure 2 - Disciplines involved in biomaterials science and the path from a need to a manufactured 
medical device (5). 
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Definitions (important concepts) 
It is difficult to pinpoint the precise origins of the term “biomaterial”. However, 
it is probable that the field we recognize today, was solidified through the early 
Clemson University biomaterials symposia in the late 1960s and early 1970s. The 
scientific success of these symposia led to the formation of the Society For 
Biomaterials in 1975 (5). 
Many definitions have been proposed for the term “biomaterial”. Initially, the 
definition, endorsed by a consensus for experts in the field, was:  
A biomaterial is a nonviable material used in a medical device, intended to 
interact with biological systems (8).  
Recently, this definition was improved: 
A biomaterial is a material intended to interface with biological systems to 
evaluate, treat, augment or replace any tissue, organ or function of the body (9). 
A complementary definition essential for understanding the goal of biomaterials 
science, is that of “biocompatibility”.  
Biocompatibility is the ability of a material to perform with an appropriate host 
response in a specific application (8). 
Regardless of their composition or application, materials used for body repair 
must meet both biofunctionality and biocompatibility.  
Biofunctionality concerns the ability of the implant material to perform the 
purpose for which it was designated. These requirements are: 
i) mechanical properties such as tensile strength, fracture toughness, elongation 
at fracture, fatigue strength, Young’s modulus;  
ii) physical properties such as density in the case of orthopedic implants, or 
thermal expansion in the case of bone cement; 
iii) surface chemistry such as degradation resistance, oxidation, corrosion, or 
bone bonding ability (10). 
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Measurement of the biocompatibility of materials 
The use of humans as research subjects, today, without several previous testing 
or knowledge of the biological properties of a material, is unethical and illegal.  
The oversight for the biological materials tests rests largely with the Food and 
Drug Administration (FDA-www.fda.gov), but these activities are also regulated by 
organizations such as the American National Standards Institute (ANSI-
www.ansi.org), the American Dental Association (ADA-www.ada.org) and the 
International Organization for Stantardization (ISO-www.iso.ch) (11). 
 
 
Biomaterials Classification (composition) 
 Varied materials, proceeding from the world of metals, ceramics, polymers and 
the composites, have been determining new methodologies and alternative treatments, 
in the fight against many diseases or in the development of new generations of soft or 
hard tissues implants (Figure 3) (6). 
 
 
 
 
Figure 3 - Biomaterials components and frequent applications in the biomedical field (6). 
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Metals 
The most commonly used metals in medical devices are the titanium, titanium 
alloys, stainless steel and cobalt-chromium alloys (7). 
Metallic implant materials have good mechanical properties (resistance, 
tenacity) comparing to other materials like polymers and ceramics. This is the reason 
for its preferential use in structural applications, such as joint prosthesis, osteosintesis 
plates, fixation screws and dental implants. One important property of these materials 
is the corrosion resistance, because of the material oxidation by the hostile human 
body environment. Besides the implant fragility, also occurs the release of corrosion 
products in the surrounding tissues, with unwanted effects (12). 
The metallic materials and metal alloys applied clinically as implants, 
presenting those described properties, are exposed in table 1 (11). 
 
 
Material Composition 
Fe-18Cr-14Ni-3Mo 
Stainless steel 
Fe-21Cr-9Ni-4Mn-3Mo-Nb-N 
Co-28Cr-6Mo 
Cobalt-chromium alloys 
Co-35Ni-20Cr-10Mo 
Titanium Ti (>99.9) 
Ti-6Al-4V 
Ti-3Al-2.5V Titanium alloys 
Ti-6Al-7Nb 
Table 1 - Implantable metals and metal alloys with clinical application. Adapted from (11). 
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Ceramics  
Ceramics, glasses and glass-ceramics include a broad range of inorganic/non-
metallic compositions, generally used to repair or replace skeletal hard connective 
tissues (13, 14). They can be classified according to the tissue response type, its 
morphological and chemical characteristics. 
Bioceramics classification based on the tissue response 
To classify the bioceramics according to the tissue response is necessary to 
know the definition of bioactivity.  In a simple way, Hench defined bioactivity as a 
characteristic of an implanted material that allows the formation of a union with the 
living tissue (15, 16). 
Classification/definition/examples: 
Bioinactive (nearly inert) - stable bioceramics without appreciable reaction with 
the implant environment (5). The material is nontoxic and biologically inactive and is 
characterized by the formation of fibrous tissues of variable thickness (13). 
Bioactive - bioceramics characterized by the direct bone attachment, without 
connective tissue formation between each other (5). The material is nontoxic and 
biologically active. Some even more specialized compositions of bioactive glasses 
will bond to soft tissues as well as bone (13). 
Biodegradable or reabsorbable - bioceramics that, after implantation, dissolves 
in time and are replaced by natural tissue. They are nontoxic materials. The rate of 
dissolution increases with decreasing calcium-to-phosphorus ratio, and consequently, 
tricalcium phosphate, with a Ca:P ratio of 1:5, is more rapidly resorbed than 
hydroxyapatite (5, 9, 11, 13, 14). 
Osseoconduction - is the ability of a material to encourage bone growth along 
its surface when placed in the vicinity of viable bone or differentiated bone-forming 
cells (e.g. Hidroxiapatite - HA) (13). 
The classification of the different types of bioceramics, according to its 
biological activity, is given in table 2 (5). 
HA is the typical and unique example of a bioceramic with direct bone union, 
characterized by a similar composition to the bone mineral phase. The bone union of 
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the other called bioactive bioceramics is a result of the previous formation of a HA 
layer on its surface (14). 
A common characteristic of bioactive glasses and glass-ceramics is a time-
dependent kinetic modification of the surface that occurs upon implantation. The 
surface forms a biologically active carbonated HA layer that provides the bonding 
interface with tissues. The collagenous constituent of soft tissues can strongly adhere 
to the bioactive silicate glasses (13). 
Bonding to bone was first demonstrated for a compositional range of bioactive 
glasses that contained SiO2, Na2O, CaO and P2O5 in specific proportions (16). There 
are three key compositional features to these bioactive glasses that distinguish them 
from traditional soda-lime-silica glasses: 
1- less than 60 mol% SiO2, 
2- high Na2O and CaO content, 
3- high CaO/P2O5 ratio. 
These features make the surface highly reactive when exposed to an aqueous 
medium (13). 
Many bioactive silica glasses are based upon the formula called 45S5, 
signifying 45 wt.% SiO2 (S = the upon network former) and 5:1 ratio of CaO to P2O5 
(13). 
 
 
Bioinactive Bioactive Biodegradable 
• Alumina (Al2O3) 
• Zircon (ZrO2) 
• Al2O3-ZrO2 composites 
• Carbon 
• Hidroxiapatite - HA 
[Ca10(PO4)6(OH)2] 
• Biological apatites 
(Enamel, Dentin and Bone apatites) 
• Tricalcium phosphate-
TPC  
[Ca3(PO4)2] 
Table 2 - Types of bioceramics according to its biological activity. Adapted from (5). 
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Other Bioceramics classifications: 
Nearly inert crystalline ceramics 
High-density, high-purity (>99.5%) alumina is used in load-bearing hip 
prostheses and dental implants due to its excellent corrosion resistance, good 
biocompatibility, high wear resistance and high strength (13). 
Porous ceramics 
The potential advantage offered by a porous ceramic implant is its inertness 
combined with the mechanical stability of the highly convoluted interface that 
develops when bone grows into the pores of the ceramic. The mechanical 
requirements of prostheses, however, severely restrict the use of low-strength porous 
ceramics to nonload-bearing applications. When load-bearing is not a primary 
requirement, porous ceramics can provide a functional implant. When pore size 
exceed 100µm, bone will grow within the interconnecting pore channels near the 
surface and maintain its vascularity and long-term viability. In this manner, the 
implant serves as a structural bridge or scaffold for bone formation (13). 
Commercially available porous products originate from two sources: hydroxyapatite 
converted from coral (e.g. ProOsteon) or animal bone (e.g. Endodbon) (14). 
Calcium Phosphate ceramics 
Bone typically consists, by weight, in 25% of water, 15% of organic materials 
and 60% of mineral phases. The mineral phase consist primarily of calcium and 
phosphate ions, with traces of magnesium, carbonate, hydroxyl, chloride, fluoride and 
citrate ions. Hence calcium phosphates occur naturally in the body, but they occur 
also within nature as mineral rocks and certain compounds can be synthesized in the 
laboratory (13). Table 3 summarizes the mineral name, chemical name and 
composition of various phases of calcium phosphates (13). 
The clinical application of calcium phosphate ceramics is largely limited to 
non-major-load-bearing parts of the skeleton because of their inferior mechanical 
properties and it was partly for this reason that interest was directed toward the use of 
calcium phosphate coatings on metallic implants substrates (13). 
Calcium phosphate-based bioceramics applications include dental implants 
(Al2O3, HA, Bioactive glasses), periodontal treatment (HA, HA-PLA composite, 
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trisodium phosphate, calcium and phosphate salts, bioactive glasses), alveolar ridge 
augmentation (Al2O3, HA, HA-autogenous bone composite, bioactive glasses), 
orthopedics ,  maxillofacial surgery and otolaryngology (13). 
 
 
Ca:P Mineral name Formula Chemical name 
1.0 Monetite CaHPO4 Dicalcium phosphate (DCP) 
1.0 Brushite CaHPO4.2H2O 
Dicalcium phosphate  Dihydrate 
(DCPD) 
1.33 - Ca8 (HPO4)2 (PO4).5(H2O) Octocalcium phosphate (OCP) 
1.43 Whitlockite Ca10 (HPO4) (PO4)6 - 
1.5 - Ca3 (PO4)2 Tricalcium phosphate (TCP) 
1.67 Hydroxyapatite Ca10  (PO4)6 (OH)2 - 
2.0 - Ca4 P2 O9 Tetracalcium phosphate 
Table 3 - Various phases of calcium phosphate ceramics. Ca:P ratio, mineral name, chemical name and 
composition. Adapted from (13). 
 
 
The calcium silicate cements could be considered in this bioceramics 
classification, according to its composition and behaviour in the biological 
environment. However, it will be further explored and discussed in detail in a later 
chapter. 
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 Polymers 
Polymers represent the largest class of biomaterials used in biomedical devices 
that include orthopaedic, dental, soft tissue and cardiovascular implants. They are 
long-chain molecules that consist of a large number of small repeating units and may 
be derived from natural sources or from synthetic organic processes (17). In table 4 
are mentioned examples of polymers according to its origin (17-19). 
 
 
Synthetic Polymers Natural Polymers 
Acrylic materials 
(eg. Polymethyl-methacrylate-PMMA) 
Epoxy Resins 
Fluoropolymers 
(eg. Polytetrafluoroethylene-PTFE) 
Collagen 
(Type I to V) 
Polyamide 
(eg. Nylon 6/6) 
Polyesters (ester group -COO-) 
Polyethylene (PE) 
Polypropylene (PP) 
Hyaluronic acid 
Polyvinylchloride (PVC) 
Silicone 
(eg. Polydimetilsiloxano-PDMS) 
Polyurethane 
Chitosan 
Table 4 - Synthetic and natural polymers used in biomedical devices. Adapted from (17-19). 
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Methods of synthetic polymers preparation fall into two categories: addition 
polymerization (chain reaction) and condensation polymerization (stepwise growth) 
(17). 
PVC, PE and PMMA are relevant examples of additions polymers used as 
biomaterials. Nylon and PET are typical condensation polymers and are used in fiber 
or fabric form as biomaterials (17). 
Natural polymers offer the advantage of being very similar, often identical, to 
macromolecular substances which the biological environment is prepared to 
recognize and to deal with metabolically. Many polymers available today are 
virtually nondestructible in biological systems, e.g., PTFE (commercial name Teflon) 
or PE. Those materials have to be removed surgically. In short-term applications, that 
require only the temporary presence of a device, a degradable material is of value. 
Degradable polymers are used in many fields such as barrier membranes, drug 
delivery, guided tissue regeneration (in dental applications), sutures or orthopaedic 
applications. An example of a synthetic degradable polymer is the polyesters, and a 
natural polymer, the collagen. Degradable polymers must fulfil more stringent 
requirements in terms of their biocompatibility than nondegradable because of the 
potential toxicity of the implant’s degradation products (17). 
 
  
 Composites 
The word composite means “consisting of two or more distinct parts”. This 
definition fits into many materials such as the metal alloys and the polymeric 
materials, at the atomic and microstructural level, or such as bone and tendon at the 
molecular and microstructural level. So, in the biomaterials context, composites can 
be considered materials consisting of two or more chemically distinct constituents, on 
a macroscale, having a distinct interface separating them. Such composites consist of 
one or more discontinuous phases embedded within a continuous phase. The 
discontinuous phase is usually harder and stronger than the continuous phase and is 
called the reinforcement or reinforcing material, whereas the continuous phase is 
termed the matrix (20). 
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A commonly accepted classification scheme of composite materials, based on 
the geometry of a representative unit of reinforcement, is exposed in Figure 4 (20). 
The main reinforcement materials that have been used in biomedical 
composites are carbon fibers, polymer fibers, ceramics and glasses. Depending upon 
the application, the reinforcements have been either inert or absorbable. The most 
common matrices are synthetic nonabsorbable polymers. To bond these phases 
together, is necessary the alteration of the surface texture of the filler (reinforcement) 
or the introduction of coupling agents: molecules that can react with both filler and 
matrix (20). 
Examples of biomedical composite systems (21, 22): 
- Dental application: Bis-GMA/inorganic particles; Silorane/inorganic 
particles; ORMOCER. 
- Bone regeneration: high-density polyethylene/hydroxyapatite particles 
(HAPEXTM); monomeric matrix/inorganic particles (Cortoss). 
 
 
Figure 4 - Classification of composite materials according to the type of the reinforcement and it’s 
disposition (20).  
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Cements as biomaterials 
In the attempt to introduce the cements in the biomaterials classification, it was 
found that it doesn’t exist a specific and defined group were fit them. This is probably 
due to its diversity in composition and application fields. 
According to its applications, they can be classified as dental cements - Table 5 
(11, 23), and bone cements - Table 6 (24, 25). The cements composition and the 
setting reaction type may be another classification to be considered - Table 7 (11, 23-
26). They are included in the classification of a biomaterial (defined bellow) and can 
be also classified according to its bioactivity. 
 
Cement Application 
Zinc Phosphate Luting, Cavity Liner, 
Zinc Polycarboxilate Luting, Cavity Liner, Orthodontic attachment 
Glass Ionomer Luting, Cavity Liner, Restoration, Orthodontic attachment 
Resin cements Luting, Orthodontic attachment 
Zinc Oxide-Eugenol Restoration, Luting (temporary or long-term), Root-end filling 
Calcium Hydroxide Cavity Liner (direct pulp capping), Root treatment 
Mineral Trioxide Aggregate Root-end filling, Root-repair, Pulp capping 
Table 5 - Dental cements - application fields. Adapted from (11, 23). 
 
After these concepts to better understand the role of cements in medical 
applications, this investigation work will focus on calcium silicate cements. The 
Highly Focalized Thermotherapy (HFT) proposed in this study for the solid tumours 
treatment, works with a Ferrrimagnetic Cement (FC) that has a chemical composition 
very similar to the calcium silicate cements, as well as its behaviour in the biological 
environment. 
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Cement Application 
PMMA cement Grafting material (cannot induce new bone formation) 
PMMA-based cements 
(adition active glass-ceramics) 
Grafting material (induces new bone formation) 
Calcium phosphate cement 
(HA, TCP) 
Grafting material (osteoinduction, osteoconduction) 
(mechanical weakness) 
Calcium silicate cements 
(MTA, Portland) 
Root-end filling, Root-repair, Pulp capping 
Table 6 - Bone cements - application fields. Adapted from (23, 24). 
 
 
Cements Reacting components Reaction type 
Zinc Phosphate Zinc and Magnesium oxide + 
Phosphoric acid 
Acid-base 
Zinc Polycarboxilate Zinc and Magnesium oxide + 
Polyacrylic acid 
Acid-base 
Glass Ionomer Fluoroaluminosilicate glasse + 
Polyacrylic acid, Polybasic 
carboxylic acid, water 
Acid-base 
Resin cements Mathacrylate monomers, fillers Light and/or chemical activated 
polymerization 
Zinc Oxide-Eugenol Zinc oxide + Eugenol Acid-base 
Calcium silicate cements 
(MTA, Portland) 
Calcium oxide, Silicon + Water Hydration reaction 
MMA-based cements Polymethylmethacrylate base + 
aditives 
Polymeric reaction 
Calcium phosphate 
cement (HA, TCP) 
Tetracalcium phosphate + Dicalcium 
phosphate 
Salts dissolution in the aqueous 
system and the final product is HA 
Table 7 - Cements classification according to its composition and the setting reaction. Adapted from 
(11, 23-26). 
 
Introduction	  	  
	   17	  
Calcium Silicate Cements 
Calcium silicate cements, mainly Portland derived cements such as mineral 
trioxide aggregate (MTA) and others, have been designed and are used for dental 
clinical applications (27-33). Calcium silicate cements possess hydraulic properties 
and spontaneously set in the presence of water (34). In addition, they release calcium 
during their hydration and setting reaction (27, 35–37) and induce the formation of 
apatite deposits when immersed in phosphate-containing solutions (28, 36–43).  
The self-setting properties of calcium silicate cements are due to the 
progressive hydration reaction of the orthosilicate ions (SiO44–). When calcium 
silicate particles react with fluids (water), a nanoporous amorphous calcium silicate 
hydrate gel (CSH gel) forms on the cement particles, whereas calcium hydroxide 
(Ca(OH)2) (portlandite) nucleates and grows in the available voids and pore spaces 
(28). CSH gel polymerizes and hardens over time, forming a solid network, which is 
associated with an increased mechanical strength (28). Figure 5 shows Scanning 
Electron Microscopy (SEM) micrographs of tricalcium silicate (Ca3SiO5) paste disks 
surfaces, before and after soaking in Simulated Body Fluid (SBF) for various times. 
Before soaking, the paste showed compact structure with some micropores (Fig. 5a 
and b). After soaking for 1 day, the micropores disappeared, cracks appeared, and 
tiny ball-like particles were observed on the surface of the samples (Fig. 5A and B). 
After soaking for 3 days, a HA layer was formed on the surface (Fig. 5C). The higher 
magnification SEM micrograph showed that the particles of HA were lath-like and 
many of these particles formed agglomerates (Fig. 5D). After soaking for 7 days, 
some micropores were formed on the surface and the HA layer became compact (Fig. 
5E and F). 
Soluble Ca(OH)2 is released by the cement surface and increases the alkalinity 
of the surrounding environment (28, 37, 43). Figure 6, the Energy Dispersion 
Spectroscopy (EDS) analysis, shows the concentration changes of calcium (Ca), 
phosphorus (P) and silicon (Si) as well as the changes of pH values of the SBF 
solution after soaking for various periods during the initial 1 day. The Ca and Si 
concentrations in the SBF solution increased steeply with a corresponding decrease in 
the P concentration. This reflected the dissolution of the Ca and Si accompanied with 
simultaneous uptake of P from the solution onto the paste, which corresponded to a 
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quick increase of the pH value of the SBF solution and deposition of calcium 
phosphate. After prolonged soaking from 1 to 7 days, the Ca and Si concentrations 
continued to increase with a corresponding decrease in the P concentration indicating 
that the P ion was used up to form the HA (28). 
One of the most popularly used calcium silicate cements is the MTA. It was 
introduced at Loma Linda University in 1993 (44) for the repair of lateral root 
perforations. In the last years, it has been widely used as a promising biomaterial for 
perforation repair, root end fillings (as a retrofill material), pulp capping, 
pulpotomies, and as an apical seal in incomplete apex formation for apexification 
procedures, or in dentin hypersensitivity (45-49). 
MTA will be detailed described in this chapter, characteristics and biological 
behaviour, because it as a chemical composition similar to the experimental cement 
used in the present investigation. The MTA patent (47) shows that it contains calcium 
oxide (CaO) and silicon (SiO). Several investigations have reported that the main 
elemental components of MTA are calcium and silica, as well as bismuth oxide (50- 
52). It is currently marketed in 2 forms: gray (GMTA) and white (WMTA). MTA 
was introduced in gray, but because of the discoloration potential of GMTA, WMTA 
was developed (53). Investigations showed that lower amounts of iron, aluminum, 
and magnesium are present in WMTA than in GMTA (51, 52, 54, 55). 
Recently, some studies have compared MTA with Portland cement, concluding 
that the principle ingredients of Portland cement (Sufiyan Cement Co, Tabriz, Iran) 
are similar to those of MTA, which include calcium phosphate, calcium oxide, and 
silicate (56). MTA contains some bismuth oxide, which increases MTA radiopacity, 
but Portland cement lacks this ingredient (27, 57). 
Initially, the bioactivity of MTA was attributed to its ability to produce 
hydroxyapatite crystals in the presence of phosphate-buffered saline (PBS) (36, 41). 
Subsequent studies showed that the interaction of MTA and Portland cement with a 
phosphate-containing fluid produces calcium-deficient B-type carbonated apatites via 
an amorphous calcium phosphate phase (37, 38, 58).  
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Figure 5 - SEM micrographs of the surfaces of a tricalcium silicate (Ca3SiO5) paste before (a, b) and 
after soaking in SBF solution for 1 day (A, B), 3 days (C, D) and 7 days (E, F) (28). 
 
 
 
Figure 6 - EDS analysis. Changes of Ca, Si and P concentrations and the pH value of the SBF solution 
after soaking with the Ca3SiO5 paste with L/P ratio of 1.0 for various times (28). 
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The biocompatibility it’s also correlated with the inflammatory response when 
the material is implanted subcutaneously or intramuscularly in animal models. Many 
studies showed that subcutaneous responses to MTA range from necrosis to 
dystrophic calcification. In addition, at first, MTA produces a moderate to severe 
subcutaneous response, which subsides at longer time intervals (59). In the 
intraosseous implantes, MTA promotes osteogenesis, as a osteoconductive material, 
with a relatively mild bone response (60). 
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1.2 – Hyperthermia  
 
Historical Development 
The first description of hyperthermia in medicine dates from the Egyptians and 
the Edwin Smith Surgical Papyrus (3000-2500 BC) (2). However, the scrolls describe 
cautery and not hyperpyrexia in the cure of chest tumours.  Indian ayurvedic 
physicians practiced local and whole body hyperthermia in 3000 BC (61). Greeks, 
from Parmenides to Hippocrates (460-370 BC), believed that heat was one of four 
body humours capable of both, causing and curing disease. Hippocrates is credited 
with submersing patients in the desert sand or in hot baths to elevate core body 
temperature and effect cure. In the late nineteenth century, William Busch and Paul 
Bruns described complete remission of a facial sarcoma and recurrent melanoma, 
respectively, in patients suffering prolonged fever from erysipelas (62, 63). William 
Coley, in the end of the eighteen-century (1893) used fever therapy as a method to 
increase temperatures. He has actively infected patients with streptococcus toxin to 
inflict fever. One inoculated patient developed a severe case of erysipelas followed by 
remission of tumours in his neck and tonsils (64). Few years later (1898), F. 
Westermark treated cervical cancer by running hot water through an intracavitary 
spiral tube. He noted excellent clinical response in the seven patients treated (65). 
This was the first application of hyperthermia for regional cancer control. In 1959, 
Barnes Woodhall perfused brain tumours with chemotherapeutics heated to 43ºC. 
They later expanded the application to head and neck cancers; however, both 
experimental groups experienced little clinical response and severe morbidity and 
mortality (66). Renato Cavaliere (1967) followed, but had limited success in 22 
patients when he used hyperthermia alone to perfuse various limb malignancies. 
Severe complications occurred, including six deaths and three immediate 
amputations; however, he did note ten patients with complete response and seven 
with 3- year disease-free survival. Their findings suggested that heat causes complete 
and selective destruction of malignant cells (67). 
In 1977, Jae Ho Kim used both, wet heat, in the form of water bath immersion, 
and inductive heat, via electromagnetic fields, to treat coetaneous malignancies. 
When added to standard radiation, 27% of patients had improved disease-free 
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survival, and when used alone, four of five patients had complete, though temporary, 
regression (68, 69). 
It is due to these pioneers that the use of hyperthermia in the cancer treatment 
has expanded, including cancers of soft tissues, bone tumours, gastrointestinal, 
neurologic, urologic, and gynaecologic origin, as well as their metastasis (2, 64–74). 
Nowadays, the several randomized studies, demonstrating that the improvements in 
treatment outcome by additional hyperthermia can be very substantial, appears to be 
the reason for the renewed interest in the hyperthermia treatment of tumours. 
 
 
Hyperthermia in the tumour treatment 
In the last decades, considerable progresses have been made in cancer therapy. 
In spite of improvements in the conventional therapies such as radiation, 
immunotherapy, surgery or chemotherapy, many cancers, particularly solid tumours, 
are still untreatable. 
Hyperthermia is a largely studied method in the tumour treatment, alone or in 
association with the conventional therapies. When administered selectively, 
hyperthermia treatment can be very potent against many types of cancer because it is 
not based on the intake of drugs by cancer cells, but on the application of heat. In a 
review work made by Overgaard J in the latest 1977 (75), about the in vivo effect of 
hyperthermia on the malignant cells, the conclusion was that heat might have 
potentials in tumour treatment. This was especially based on the following facts: 
- Hyperthermia in the range of 41-43ºC have potentials for selective 
destruction of malignant cells; 
- Heat, in sufficient doses, may kill all malignant cells in a tumour 
under environment conditions impossible, or very difficult to reach with other 
forms of treatment; 
- Heat as an effect on the non-proliferating tumour cells and may 
especially sensitize proliferating tumour cells to other treatment modalities, 
irradiation and chemotherapeutics agents. 
- In combination with irradiation/chemotherapy, hyperthermia can 
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severely affect all parts of the tumour tissue and can also substantially reduce 
the doses of highly toxic chemotherapeutic agents. 
Besides the laboratory investigation performed for many years, hyperthermia 
effectiveness as a cancer treatment, has been demonstrated by many clinical trials in 
many countries in the world (76). These trials have highlighted that hyperthermia 
improves cancer treatment results, while decreasing the side effects of conventional 
therapies. 
Hyperthermia societies such as the International Clinical Hyperthermia Society 
(ICHS), the Society of Thermal Medicine (STM), the European Society for 
Hyperthermic Oncology (ESHO), the North American Hyperthermia Society 
(NAHS) or the Asian Society of Hyperthermic Oncology (ASHO) were created to 
gather all the researchers and investigations studies in the field. A specific journal, the 
“International Journal of Hyperthermia”, is the official journal of the STM, the 
ESHO and the ASHO, and it has been published since 1979 until today. It provides a 
forum for the publication of Research and Clinical papers; invited Reviews; Clinical 
Case Reports; Rapid Communications and Letters on hyperthermia which fall largely 
into the categories: Clinical Studies, Biological Studies and Techniques of Heat 
Delivery and Temperature Measurement (http://informahealthcare.com/journal/hth). 
Hyperthermia is also recognized and recommended in many Cancer 
Associations such as the National Cancer Institute (USA) at the National Institutes of 
Health, the American Cancer Society, the International Oral Cancer Association 
(http://fightoralcancer.org/hyperthermia-combined-with-low-dose-radiation/) or the 
Cancer Treatment Centers of America (http://www.cancercenter.com). 
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How hyperthermia acts in the tumours destruction: 
 
Tumours neo-vascularisation, and Blood flow (Oxygenation/Hypoxia) 
The tumour acquisition of new in-growing vessels may occur by different 
mechanisms. Endothelial cells are normally quiescent and tightly regulated by a 
delicate balance between pro-angiogenic and anti-angiogenic molecules. In presence 
of an excessive secretion of angiogenic molecules by tumours, endothelial cells are 
stimulated and they organize themselves in vessels structure through multistep 
sequential and distinct processes, depending on tumour type and anatomic location. 
These processes include vessel cooption and angiogenesis (77). 
Vessel-Cooption is the process in which tumours take up pre-existing normal 
blood vessels and use them for their initial growth. The initial foci of neoplastic cells 
receive their nutrients and oxygen by diffusion (distance from host vessels lower than 
100-200µm)(77, 78). 
Angiogenesis - Upon adequate stimulus, endothelial cells begin to sprout from 
pre-existing capillaries and after the degradation of the extracellular matrix, migrate 
and organize themselves in capillary tube formation and ultimately in a vascular 
network (79). Tumours can establish their own blood supply by several means. Figure 
7 is a schematic of tumour-induced neovascularization. Without this abnormal 
network metastasis of several tumours, they can’t growth, which means that 
angiogenesis control can be one approach to avoid the tumour dissemination (78). 
The vascular collapse and the subsequent necrosis after hyperthermia treatment 
is due in part to the haphazard organization and construction of the cancer neo-
vascularisation. Tumour vessels are bent, coiled, maximally dilated at rest and, often 
clogged with cancer cells. In addition, the decline in available oxygen that 
accompanies heat-induced vascular collapse contributes to an overall drop in pH. 
Glycolitic metabolism and lactic acidosis, inherent to tumour cells, significantly 
increase upon heating and remain elevated for several hours (80). 
Blood flow is one of the major vehicles by which heat is dissipated from 
tissues. In general, the lower the blood flow rate, in a determined region, the easier it 
is to heat, because heat accumulates (73). The rise in temperature is physiologically 
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controlled by the afferent heat delivery and efferent flow dissipation (2). 
The appropriate physiologic response to heat is vasodilatation and the response 
of tumour vasculature is distinct from healthy vessels. Upon initial heating, blood 
flow and oxygenation in tumours increases (81). When temperatures increase above 
42ºC, vascular collapse and necrosis ensue (73, 81). Although higher temperatures 
can cause vascular shutdown with reduced perfusion and increased hypoxia (82), 
milder temperatures (below ≈ 42ºC) will typically stimulate perfusion in the tumour 
and improve oxygenation (83-86). In addition, temperature elevation will reduce the 
oxygen binding of haemoglobin, contributing to increased delivery of oxygen within 
a region of localized hyperthermia (87). 
 
 
 
Figure 7 - Mechanism of tumour angiogenesis. A: schematic of tumour blood vessel (green, normal 
tumour cells; black, necrotic tumour cells). Notice the thin walls, tortuous shape, absence of pericytes, 
and variations in diameter. Numerous gaps or fenestrae are found between endothelial cells. The vessel 
wall is mosaic and can consist of both tumour cells as well as endothelial cells. B: model of tumour- 
induced neovascularization. In i, an initially avascular tumour grows until inner regions become 
hypoxic and upregulate production of angiogenic factors such as vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), and interleukin (IL)-8. In ii, a tumour grows on an existing 
blood vessel. Soon the tumour induces angiopoietin-2 (Ang2= expression in the preexisting vessel, and 
it regresses due to endothelial cell apoptosis. The tumour is now avascular, and by upregulating 
angiogenic factors as in i, it induces the production of a new blood supply (78). 
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The tumour treatment by hyperthermia consist in the temperature increase in the 
tumour and a vascular collapse ensues due to a preferential (i) increase in red blood 
cell rigidity, (ii) endothelial cell swelling, (iii) haemorrhage into capillary lumens, 
and (iv) leukocyte adherence to vessel walls (Figure 8) (2, 80). This process is first 
seen in tissues at approximately 42ºC and overwhelms all human tissue at 45ºC  (73).  
 
 
Figure 8 - Thermal effects on tumour and cell physiology (2).  
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Cellular response 
The primitive and chaotic nature of solid tumours vascular network and blood 
supply, when compared to normal tissues, can result in areas that are nutrient-
deprived, low in oxygen and highly acidic. Cells in these adverse conditions are 
generally more sensitive to the cytotoxic effect of heat (73). 
The acidic, hypoxic, and nutrient poor condition within a cancer, subsequently 
exacerbated by hyperthermia, makes an otherwise survivable condition incompatible 
with cell life (88-90). The establishment of the neovascular supply is an attempt to 
overcome the hypoxia, but this is inefficient and irregular. The result is the 
persistence within the tumour mass of heterogeneous micro-regions of non-
proliferating hypoxic cells, which are surrounded by vital, well nourished, and 
proliferating cells. It has been demonstrated that hypoxia and acidic regions in solid 
human tumours are common (91-93). The hypoxic microenvironments are 
characterized by low oxygen tension, low extracellular pH, high interstitial fluid 
pressure, glucose deficiency, increased extracellular lactate concentration and 
tendency to metastasization (94). These tumour cells, chronically exposed to low 
extracellular pH, are relatively resistant to ionizing radiation and multidrug resistant, 
but they tend to be markedly sensitive to the thermal damage (91-93). 
Increasing the tumour temperature by hyperthermia results in increased 
translational, vibrational, and rotational motion of all molecules, including water, 
within cells. These increased motion results in more rapid reaction rates, resulting in 
both increased metabolism and transition in cellular structures such has membranes 
and macromolecules such as proteins and acid deoxyribonucleic (DNA) (95). 
Cells thermal damage will occur when the amount of heat delivered provides 
energy in the range of 100–150 kcal/mole, the range of that necessary for protein 
denaturation (95-98). The rate-limiting step in thermal damage is likely to be this 
proteins denaturation and DNA damage repair, resulting in disruption of cellular 
structure and function. Heated cells show inactivation of membrane receptors, altered 
enzyme activity, altered cellular structures, and chromosomal damage and miss-repair 
(1, 97-99).  
A characteristic effect of hyperthermia is the blocking of cells cycle (in normal 
and malignant cells), by mitotic arrest, inhibition the entrance of cells into mitosis 
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(G2 block) and probably also the progress from S to G2. In the S-phase, 
chromosomal damage is observed. S- and M-phase cells undergo a “slow mode of 
cell death” after hyperthermia, whereas those exposed to heat during G1-phase are 
relatively heat resistant and do not show any microscopic damage. These effects are 
mainly transitory, if the cells are kept under good growth conditions the proliferative 
ability is restored (1, 73, 89). 
Cell death can follow two distinct pathways, apoptosis or necrosis. 
Necrosis is the result of acute cellular dysfunction due to extreme trauma or 
injury to the cell. It is a passive and disruptive process which results in cytolysis and 
in the leakage of the dying cell’s contents into intracellular spaces, causing 
inflammation by infiltration of pro-inflammatory cells into the lesion which leads to 
further tissue damage or even death of neighbouring cells (100). 
Apoptosis is an innate and evolutionary conserved process by which cells 
systematically inactivate and disassemble their structural and functional components 
to effect their own demise. Apoptosis occurs normally during the development of 
multicellular organisms through a genetically regulated program or during the 
immune response when unwanted cells are selectively removed (101). 
 
 
Immunity induction 
 
Immune response 
Yanase et al. 1998 (102), demonstrated that hyperthermia can induce 
antitumour immunity using two tumours transplanted to both femurs of a rat. 
Although only one tumour was subjected to hyperthermia (by the direct injection of 
magnetite cationic liposomes in to the tumour), the other tumour also disappeared 
completely.  Immunocytochemical assay revealed that both CD8-positive and CD4-
positive T cells migrated in the tumours after the hyperthermia treatment. These 
results suggest that these therapeutic magnetic particles are potentially effective tools 
for hyperthermic treatment of tumours, because in addition to the killing of tumour 
cells by heat, a host immune response is induced. 
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In addition, Ito et al. 2001 (103) have revealed that the augmentation of MHC 
class I antigens on the tumour cell surface and/or the complex of heat shock protein 
(HSP) and antigen cause the immunity induction.  
To explain how tumour antigens are recognized by the host immune system, 
Kobayashi and co-workers (1, 94-105) proposed heat shock protein (HSP)-mediated 
antitumor immunity as a mechanism. 
 
Heat Shock Proteins - HSPs 
Ever since 1982 the hyperthermia is known to induce heat shock proteins - 
HSPs (106). When cultured cells or whole organisms are exposed to elevated 
temperatures, they respond by synthesizing a small number of those highly conserved 
proteins (107). Due to Schlesinger studies in 1990 (108), this concept was highlighted 
has well as the relationship between HSPs and thermotolerance, and the induction of 
the immune response. 
HSPs appear to be related to the heat effect on tumour cells essentially by 
different mechanisms: 
(i). Correlation between induction of HSPs and development of tolerance to 
subsequent thermal shock. As the expression of HSPs protects cells from heat-
induced apoptosis (109), it can be considered a complicating factor in hyperthermia. 
(ii). Use of HSPs in immunotherapy for the cancer treatment (110). 
These facts are apparently in contrast each other, but, tacking in to account their 
different mechanisms of action, a possible concatenation can exist. 
Initially, the role of HSPs appeared to involve a thermotolerance mechanism, 
protecting cells from different sources of stress. This concept will be explored and 
clarified forward in the thermotolerance topic. 
It has been demonstrated that tumour-derived HSPs, such as HSP70, HSP90 
and glucose-regulated protein 96 (gp96), can elicit cancer immunity (111, 112). In 
these proposals, since the HSPs have to be extracted from tumours in the body, 
surgery is needed. However, if hyperthermia is used, surgery and extraction will be 
unnecessary.  
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Srivastava and colleges (113-116) proposed the following “relay line model” 
for tumour antigenic peptide transfer during antigen processing and presentation by 
HSPs:  
(i) The peptides are first bound to HSP70 (or HSP90), which are responsible for 
transporting them to the endoplasmic reticulum (ER) through the transporter 
associated with antigen processing (TAP);  
(ii) the peptides are transferred to gp96 in the lumen of the ER;  
(iii) in the terminal step, gp96 transfers the peptides to the MHC class I–β2 
microglobulin complexes. 
Their study results, and those obtained by Ménoret (117), have also shown the 
importance of HSPs in immune reactions. Todryk et al. reported that induction of 
HSP70 expression led to infiltration by T cells, macrophages, and dendritic cells into 
the tumor and enhanced immunogenicity through a T cell-mediated mechanism (118). 
Wells et al. (119, 120) demonstrated that stably transfected B16 melanoma cells 
that constitutively expressed the human HSP70 exhibited significantly increased 
levels of the MHC class I antigens on their surface. 
HSPs may be important elements influencing cellular sensitivity/resistance to 
stressful conditions that potentially lead to apoptosis. 
 
 
Apoptosis 
The term apoptosis was proposed by Kerr et al. (1972) (121) but the 
mechanism was first described by Lockshin and Williams in 1964 (122). Apoptosis 
was defined as a programmed cell death and not as an accidental death mechanism.  
Apoptotic cell death acts as part of a quality control and repair mechanism by 
elimination of unwanted, genetically damaged, or senescent cells, and as such is 
critically important for the development of organisms. The major biochemical 
features of apoptosis are activation of intracellular proteases, especially caspases, and 
internucleosomal DNA fragmentation. Changes in several cell surface molecules also 
ensure that apoptotic cells are immediately recognized and phagocytised by 
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neighbouring cells in tissues, with the result that many cells can be deleted from 
tissues in relatively short time. Therefore, apoptosis results in the orderly elimination 
of cells without generating an inflammatory response (122, 123). 
 
Apoptosis and Hyperthermia 
Apoptosis can be triggered by a number of intrinsic and extrinsic signals such 
radiation, oxidative stress, transduced signals, DNA damage and hyperthermia (124, 
125). 
Hyperthermia, in the temperature range of 41-45ºC induces apoptosis to 
varying degrees in many cell lines (Graph I) (126). Transient heat resistance can be 
conferred to most cell types by treatment with mild sub-lethal heat loads, which 
allows them to escape to the apoptotic response that would normally be elicited by a 
more severe thermal injury (125, 127). 
 
 
Graph I - Many different cell lines are hyperthermia induced apoptosis competent but with varying 
degrees of sensitivity. All cell lines were heat shocked at 43ºC for 1h and assessed for apoptotic 
endpoints at 12h using either comet formation (solid line) or nuclear body formation (striped line) 
(126). 
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O’Neill et al. in 1998 found statistically significant levels of apoptosis at a 
hyperthermia temperature of 41ºC (peaking at 43ºC), and rapidly dropping with 
temperature augmentation to 45ºC and beyond. Virtually no apoptosis were 
detectable at or above 46ºC, the mode of cell death becoming nearly 100% necrotic. 
They suggest that there is a narrow apoptotic temperature window between 41-45ºC 
(126). 
 
Apoptosis pathways 
The apoptosis cascade can be initiated via two major pathways, involving either 
activation of death receptors in response to ligand binding (extrinsic or death receptor 
pathway), or the release of proapoptotic proteins, such as cytochrome c, from 
mitochondria to cytosol (intrinsic or mitochondrial pathway). The extrinsic pathway 
is triggered at the cell surface through cytokine induced death by receptor mediated 
activation of caspase-8 or caspase-10, followed by activation of caspase-3 and 
caspase-7. The intrinsic pathway is characterized by mitochondrial dysfunction, 
resulting in cytochrome c release followed by formation of apoptosomes and 
subsequent activation of caspase-9 followed by caspases-3 and -7 (122, 128, 129). 
It is now clear that caspase activation (cleavage of procaspase to active caspase) 
is a hallmark of almost all apoptotic systems. Caspase 3 is a central effector caspase 
in many cells and mediates the cleavage of itself, other downstream caspases, and 
other caspase substrates (130, 131). 
When heated to 45°C, vital proteins of the cancer cell become damaged (e.g. 
misfolded) and/or the cell membrane partially dissolves in the surrounding aqueous 
medium (132). A multitude of heat-induced deviations from the “normal” metabolism 
of a cancer cell can eventually lead to apoptosis. 
One of the newly emerging areas of interest in apoptosis is that of 
HSP/chaperone regulation of apoptotic pathways. The accumulation of damaged 
proteins within the cell may signal HSP induction, but their accumulation also 
induces apoptosis. It is evident that there exists an overlap between the signals that 
induce a protective stress response (thermotholerance) and those that initiate 
apoptosis. 
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Thermotholerance 
Thermotholerance refers to the adaptive responses of cells exposed to elevated 
temperatures. In this regard, a mild heat shock treatment conditions, induces cells to 
withstand to the effects of a subsequent temperature insult, which would otherwise be 
lethal (133). 
Thermotholerance is at least partially based on the induction of heat-shock 
proteins (HSP) and other post-transitional adaptation processes (e.g. cell cycle arrest 
in the G2-phase, changes in cell metabolism) (1). 
The induction of HSPs in response to stress and the subsequent 
thermotholerance is transient. When the stress element (heat) is removed, these cells 
continue to function normally and the levels of HSPs drop back to basal levels with 
time (134). Figure 9 and 10 help us to better understand the mechanism of cells death 
caused by stress stimulus like a temperature increase. When a cell experiences low 
level stress, it activates the stress response, which involves rapid induction of HSPs. 
Accumulation of HSPs accompanies thermotholerance and resistance to cells death. 
When the stress element is removed, the cells return to their normal activities. As the 
stress level increases, the injured cells activate their own demise and undergo 
apoptosis (134). 
However, under extreme conditions, when the stress level eliminates the 
capacity for regulated activation of apoptosis cascade, the cells undergo necrosis 
(Figure 11). Under stress conditions denaturation of functional proteins can induce 
HSPs. The chaperone function of HSPs facilitates their refolding or 
ubiquitin/proteasome-mediated degradation of these proteins. However, accumulation 
of damaged or ubiquitinated proteins, either as a direct consequence of stress or 
inhibition of proteasomal function, may lead to activation of apoptotic pathways (1, 
134).  
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Figure 9 - The effects of stress-inducing agents on cells (134). 
 
 
 
 
 
Figure 10 - Protein denaturation as common signals that can activate both stress response and 
apoptosis (134). 
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Figure 11 - Different ways by which heat shock proteins may be inhibitors of cell death (1). 
 
 
A new line of investigation based on the hypoxia and the immune system 
Hypoxia within the tumour microenvironment is correlated with poor treatment 
outcome after radiation and chemotherapy, and with decreased overall survival in 
cancer patients. Several molecular mechanisms by which hypoxia supports tumour 
growth and interferes with effective radiation and chemotherapies are now well 
established. However, several new lines of investigation are pointing to yet another 
ominous outcome of hypoxia in the tumour microenvironment: suppression of anti-
tumour immune effector cells and enhancement of tumour escape from immune 
surveillance. Hypoxia incapacitates several different types of immune effector cells, 
enhances the activity of immunosuppressive cells and provides new avenues which 
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help 'blind' immune cells to detect the presence of tumour cells. Mild thermal therapy, 
through its physiologically regulated ability to alter vascular perfusion and oxygen 
tensions within the tumour microenvironment, as well as its ability to enhance the 
function of some of the same immune effector activities that are inhibited by hypoxia, 
could be used to rapidly and safely release the tight grip of hypoxia in the tumour 
microenvironment thereby reducing barriers to more effective immune-based 
therapies. Although the mechanism is far from clear, local hyperthermia can increase 
oxygenation of tumours and increase vascular perfusion in experimental tumour 
models. Thus treatment with heat could have a two-pronged ability to improve anti-
timour immunity: reduced hypoxia-mediated immune suppression via heat-induced 
vascular changes in tumour microenvironment and direct stimulation of anti-tumour 
immune mechanism (135, 136). These heat response mechanisms are temperature 
dependent and this question will be discussed below in the point related to the dose-
response relationship with thermal cell killing. 
 
 
Increasing the temperature. How much? 
 
Dose-response relationship with thermal cell killing 
The hyperthermia in the cancer treatment refers to the temperature increase of 
the tumour tissues to values between 41ºC and 46ºC. Higher temperatures, up to 
56ºC, produce the “thermo-ablation”, yielding widespread necrosis, coagulation or 
carbonization (depending on the temperature)(137). 
Mild hyperthermia (41ºC) causes an increase in blood flow, increasing the 
oxyhaemoglobin saturation and consequently the oxygen availability, improving 
tumour oxygenation status. At higher temperatures, the transient increase in blood 
flow will cause the vascular damage that will rapidly lead to a decrease in tumour 
blood flow and the corresponding decrease in oxyhaemoglobin saturation that will 
result in a decrease in overall oxygen availability. In consequence of the oxygen 
decrease, the tumour pH will also decrease leading to ischemia and cell death (1). 
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In culture cells exposed to a defined temperature, between 41 and 47ºC, a dose-
effect curve can be defined by plotting the rate of cell death against the duration of 
hyperthermia. The corresponding survival curves show a typical “shoulder” that 
reflects a two-step process of cell killing. This is marked by a linear growth arrest in 
the beginning of heat exposure (reflecting a reversible, non-lethal heat damage) that is 
followed by exponential cell death. The capability to induce cell death at lower 
temperatures <42-43ºC is markedly lower than above 43ºC (1, 138, 139). In the figure 
12 it is possible to observe this phenomenon in asynchronous Chinese hamster 
ovarian cells heated at different temperatures (1). 
 
 
Figure 12 – Dose-response relationship of thermal cell killing. Schematic drawing of the surviving 
fraction of asynchronous Chinese hamster ovarian cells heated at different temperatures, emphasizing 
the typical “shoulder” (1). 
 
 
It has been reported that the cytotoxic effect of mild temperature hyperthermia 
(MTH) alone, around 41ºC, is decreased in accordance with the development of 
chronic thermotolerance (140). Nevertheless, this modality has recently drawn 
attention in cancer therapy owing to findings that most human tumour cell lines are 
more sensitive to MTH than rodent cells (73, 141, 142). In addition to its direct 
cytotoxic effects, MTH is also reported to provide a number of other clinical 
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advantages, including immunostimulatory effects against tumours, improvement of 
oxygenation, and positive effects on drug delivery via enlargement of vessel pore size 
in tumour tissue (85, 143, 144). 
 
 
Dose-response relationship with cell tumour type - mouse melanoma 
Hyperthermia treatment of solid tumours is dependent on the time and 
temperature of heating and on the tumour type.  
Ito et al. (2003) used a melanoma mouse model to examine the feasibility of the 
combination therapy using intracellular hyperthermia with magnetic cationic 
lipossomes (MCLs) and it has been shown an obvious antitumour effect using 43ºC 
for 30 minutes (145). Suzuki et al. (2003) used magnetic cationic liposomes injected 
into mouse melanoma nodules (B16F10), which were then subjected to an alternating 
magnetic field (AMF) during 30minutes. The animals group subjected to the AMF 
once at 43ºC showed no regression, animals subjected to the AMF once at 46ºC 
showed 40% regression and animals subjected to the AMF twice at 46ºC sowed 90% 
regression. They also experimented the rechallenge of the cured mice and they 
observed that 66% of those mice rejected the melanoma cells. This findings support 
the theory that hyperthermia can kill the tumour cells not only by heat and but also by 
inducing an immune response (146). In the same melanoma mouse model (B16F10) 
Saito et al. (2008) applied a method of magnetically-induced hyperthermia using 
thermosensitive ferromagnetic particles (FMPs) with low Curie temperature (Tc = 
43ºC). This means that the material will be heated to 43ºC but after that temperature 
the magnetic properties of the particles will change and temperature will remain 
almost constant. FMPs were injected into the tumours and one group was submitted 
to an exposure to the magnetic field (30 minutes) and the other was exposed twice a 
week for 4 weeks. The repeated exposure was more effective in the prolongation of 
the animal’s life (30-45 days in the first group and 120 days in the second group). 
Their findings suggest that repeated treatment with magnetically-induced self-
regulating hyperthermia, mediated by FMPs with a low Tc, is a effective means of 
suppressing the melanoma growth (147). 
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Balivada et al. (2010) evaluated the influence of biomagnetic nanoparticles 
(MNPs) given systemically or intratumorally, combined with short external AMF 
exposure (10 minutes, 3 exposures, temperature increase 11ºC) on the subcutaneous 
mouse melanomas (B16F10) and they concluded that this methodology can 
significantly attenuate the tumour growth by the effect of local hyperthermia obtained 
(148). 
 
 
Hyperthermia as an adjuvant treatment 
 
Radiotherapy and Chemotherapy 
Localized hyperthermia is a powerful therapeutic modality. The results from 
experimental studies indicate that hyperthermia is both the ideal complementary to, 
and a strong sensitizer of, radiotherapy and many cytotoxic drugs (76). 
The inherent acidity and low oxygen tension in tumours can provide resistance 
to both chemotherapy and radiation; however, these same factors render cells more 
susceptible to heat. The cytotoxicity of several antineoplasic drugs and the efficacy of 
radiation are enhanced at higher temperatures, as described below in the dose-
response relationship with thermal cell killing (149-152). 
Multicenter trials demonstrated significant benefits in local and regional control 
and overall survival for patients receiving a combination of chemotherapy and 
radiotherapy compared with those receiving treatments alone (153). 
 
Immunotherapy 
It was already been described in this work the importance of the HSPs, induced 
by the hyperthermia treatment (particularly HSP 70, HSP90 and glucose-regulated 
protein 96), in the immune reaction (116, 117). HSP-mediated antitumor immunity 
was reported to cause a vaccine effect due to HSP-peptide complexes purified from 
human melanoma cells (154). With regard to the mechanism of antitumor immunity 
induced by hyperthermia, Ito et al (103, 104) demonstrated that HSP70 expression 
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occurs during hyperthermia-induced antitumor immunity against the T-9 rat glioma. 
This hyperthermia system leads to vaccination with HSP70-peptide via necrotic 
tumour cell death in vivo, resulting in antitumor immunity. This phenomenon, which 
may be called in situ vaccination, has numerous implications in the development of 
novel antitumor therapies based on hyperthermia.  Based on these results, the same 
author suggests the efficacy of the combination therapy of intracellular hyperthermia 
(with magnetic cationic lipossomes - MCLs) at 43ºC and immunotherapy (with 
Interleukin-2 (IL-2) - a potent stimulator of lymphocyte proliferation and which 
augments the activity of cytotoxic T lymphocytes or with Granulocyte-macrophage 
colony-stimulating factor (GM-CSF) - a hematopoietic growth factor that stimulates 
proliferation and differentiation of granulocytic and monocytic progenitor cells). 
Although this study had not elucidated the roles of IL-2 and GM-CSF in combination 
with hyperthermia, a complete regression of tumours was observed after the 
combination therapy (145). 
 
 
Clinical application of Hyperthermia methods 
Modern hyperthermia, using sophisticated computer-controlled heating devices 
and invasive multisensor thermomethry, has been applied clinically for about 20 
years (3). In the clinical application of hyperthermia, it can be distinguished the local 
and the whole body hyperthermia. 
 
Local hyperthermia (Local/interstitial and regional hyperthermia) 
The aim is to increase mainly the tumour temperature. Local hyperthermia can 
be applied by external, intraluminal or intersticial methods. Electromagnetic or 
ultrasound energy is directed at the treatment volume. The volume that can be heated 
depends on the physical characteristics of the energy source and on the type of 
applicator (155).  
Methods for applying hyperthermia externally can be divided into superficial 
techniques (the energy coming from one direction) and deep, also termed regional 
hyperthermia (energy directed from around the part of the body in which the target 
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volume is located) as shown in figures 13 and 14 (76). Those deep techniques are the 
hyperthermic perfusion techniques. They are applied by perfusion of a limb, organ or 
body cavity with heated fluids (156, 157), as the hyperthermic isolated limb perfusion 
(HILP) or the hyperthermic peritoneal perfusion (HPP). The technique of continuous 
hyperthermia peritoneal perfusion is illustrated schematically in figure 15. 
 
 
 
 
Figure 13 – Example of a clinical local external hyperthermia application. A – patient with recurrent 
breast cancer; B – patient during deep hyperthermia treatment (http://sennewald.de/hyperthermia/). 
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Figure 14 - Example of a commercially available hyperthermia device for regional hyperthermia - 
‘BSD-2000’ (45,76).  
 
 
 
 
Figure 15 - Schematic representation of the open continuous perfusion technique. Following 
cytoreduction, the abdominal wall is sutures to a retractor frame fixed on the operating table (1). The 
frame itself is covered by a plastic sheet with a small slit accommodating the surgeon’s hand. A 
Tenkhoff-type inflow catheter is placed centrally, and multiperforated outflow drains are placed in left 
and right subdiaphragmatic space and pelvis. Continuous perfusion is established with a roller pump. 
Thermocouple probes are placed in the vicinity of the drains; central temperature is monitored with 
oesophageal or pulmonary artery catheter probes (157). 
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Whole body hyperthermia 
Several methods have been used for the whole body hyperthermia (WBH) 
achievement. Energy is introduced into the body, while at the same time energy 
losses are minimised (76, 158, 159). However, the application of WBH is relatively 
invasive and accompanied with a broader spectrum of toxic effects than local/regional 
hyperthermia. On the other hand, WBH is part of a systemic therapy with the 
potential to treat metastatic disease (1). In figure 16 are shown some methods used in 
the WBH applications (157). 
The first randomised studies performed in the United States failed to show 
evidence of a beneficial effect from hyperthermia due to the use of inadequate 
treatment techniques (76). 
 
                   
                 
Figure 16 - Whole body hyperthermia equipments. A - European Society for Hyperthermic Oncology. 
B - Heckelbed_small (UTHealth, University of Texas; Health Science at Houston). C and D - 
‘IRATHERM-2000’ radiant heat applicator (WBH) hyperthermia system (1). 
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Due to the limited in vivo temperature data (thermometry) available, the clinical 
limitation and potentials of hyperthermia can only be understood with the help of 
hyperthermia treatment planning. Is necessary to design, control, document and 
evaluate a treatment and thus to provide the data for treatment optimization and to 
provide the insight to design better heating equipment (3). The treatment techniques 
vary according to the method used to produce heat. 
The most commonly used heating method in clinical settings is the capacitive 
heating using a radiofrequency (RF) electric field (160). However, specifically 
heating tumours by capacitive heating using an RF electric field is difficult, because 
the heating characteristics are influenced by various factors, such as tumour size, 
position of electrodes, and adhesion of electrodes at uneven sites. From a clinical 
point of view, a simple heat mediator is preferable for superficially seated tumours 
such as coetaneous melanoma (145). 
The focal hyperthermia produced using either radiofrequency, microwave, or 
laser are currently used for local ablation of liver tumours (161). The mechanisms of 
action of the various techniques are similar, based on focal heat production to achieve 
tumour destruction (162). 
In the last years, many in vitro and in vivo studies have been performed based 
on the Magnetically mediated hyperthermia (MMH) concept. Even clinical trials, 
using different MMH methodologies, are in course for the local treatment of tumours 
and their metastasis. Since this is the base of the present study, it will be discussed 
below, in detail. 
The well-established concept of using hyperthermia in the tumour treatment 
and the limitations of the available methodologies to produce hyperthermia is a 
motivation for the constant investigations in course in this field (Table 8) (163-167). 
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Table 8 - Experimental methods to produce hyperthermia design for the tumours treatment (163-167). 
 
 
Magnetically mediated hyperthermia 
The magnetically mediated hyperthermia technique consists of localizing 
magnetic particles or seeds within tumour tissue and then applying an external AMF 
to cause them to heat by hysteresis loss, Neel relaxation or induced eddy currents. 
This heat then conducts into the surrounding cancerous tissue (4). 
The first reported study using these methodology was realised by Gilchrist et al. 
in 1957, to treat lymphatic metastases of large bowel cancer with heat, by allowing 
microscopic ferromagnetic particles to embolize in lymph nodes draining the primary 
cancer site and then applying an external alternating magnetic field to cause 
hysteretic heating of the particles (168).  
In this context, the important properties of magnetic particles are non-toxicity, 
biocompatibility, injectability, high-level accumulation in the target tumour and 
effective absorption of the energy of alternating magnetic fields (169). 
Moroz et al., 2002 (4) suggest a classification for the MMH techniques 
available to be used the tumour treatment. This classification consist in four sub-
class: -­‐ Arterial Embolization Hyperthermia - the arterial supply of a tumour 
is used as a pathway to carry ferromagnetic particles in to the tumour tissue 
followed by exposure to an alternating magnetic field; the heat originates 
from ferromagnetic particles within blood vessels. 
Authors Experimental hyperthermia methods 
Shinkai, 2001 Antibodyconjugated magnetoliposomes (ACMs). 
Kubes 2008 Local microwave hyperthermia 
Lee, 2010 TiO2 nanotubes as a therapeutic agent for cancer treatment 
Andronescu, 2010 Collagen/hydroxyapatite: magnetite composite material for bone cancer 
Nuccitelli, 2010 Nanosecond pulsed electric field therapy 
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-­‐ Direct Injection Hyperthermia - the tumour is directly injected with 
ferromagnetic particles before exposure to an alternating magnetic field; the 
heat originates from extracellularly deposit particles. -­‐ Intracellular Hyperthermia - the particles usually have same form of 
coating, they are delivered to the tumour by either arterial embolization or 
direct injection and the they are selectively ingested by the tumour cells, with 
minimal uptake by normal cells; the heat then generated on exposure to an 
alternating magnetic field originates from within the tumour cell; involves the 
use of magnetic fluids containing sub-domain sized particles that generate 
heat via Neel relaxation. -­‐ Interstitial Implant Hyperthermia - surgically implantation of 
ferromagnetic rods or seeds directly into tumour tissue before exposure to an 
alternating magnetic field; has been used to treat human tumours. 
 
 
MMH methods classifications: 
 
Magnetic Fluid Hyperthermia 
Jordan et al. (1993, 1996) have proposed the magnetic fluid hyperthermia 
(MFH) in several comprehensive in vitro studies. They confirmed the excellent power 
absorption capabilities of this hyperthermia modality, which may be attributed to the 
much larger number and surface of heating elements (170, 171). 
In this technique, the energy is coupled magnetically to superparamagnetic iron 
oxide nanoparticles with a core diameter of 15 nm. After direct intratumoral injection 
of magnetic fluids into the target region, the particles are selectively heated in an 
externally applied AC magnetic field. 
In vivo studies have documented significant antitumor effects of MFH in many 
carcinoma models. Theoretically, homogeneous thermoablative intratumoral 
temperatures can be obtained with MFH if infiltration and intratumoral distribution of 
magnetic fluids are optimal. Nevertheless, such an optimal infiltration may be 
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difficult to achieve clinically, depending on the anatomy of the organ and regional 
factors, most importantly perfusion. On the other hand, intratumoral distribution is 
also influenced by the intrinsic tendency of magnetic fluids to spread within the target 
tissue. This is the major reason why further preparations of ferrofluid formulations 
with both optimal intratumoral distribution and stable deposition are under 
development (172-178). 
 
Magnetosensitive Gels 
These materials are usually polymer networks sustaining solution containing 
magnetic particles, microferrimagnetic particles (179-181). These particles are 
delivered into the tumour either by transarterial catheter injection of its specific 
supply, or by direct injection into the tumour body (72, 169, 182). 
Same gels like agar (169), carrageenan (182) and bridging anionic 
bis(ethylhexyl) sodium sulfosuccinate reverse micelles (72) gels were used to obtain 
uniformly embedded magnetic particles. 
 
Dextran magnetite nanoparticles 
Some researchers have proposed intracellular hyperthermia and developed 
submicron magnetic particles for hyperthermia, the dextran magnetite nanoparticles.  
Gordon et al. first proposed this concept in 1979 (183). 
 
Modified Dextran Magnetite  
Chan et al. (1993) reported on modified dextran magnetite and its hyperthermic 
effect by using several human carcinoma cell lines in vitro. The specific absorption 
rate (SAR), which indicates the heat evolution rate in hyperthermia, of conventional 
dextran magnetite is low. Dextran magnetite behaves as a super-paramagnetic particle 
rather than a ferromagnetic particle due to its small size; hence, its hysteresis loss is 
very low. Those authors controlled the oxygen concentration in the preparation of 
dextran magnetite and selected particles of approximately 15 nm (184).  
Shinkai et al. (1994) have reported that particle size is a critical factor in 
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obtaining a high SAR value (185). 
 
Magnetite Cationic Liposomes 
Schneider et al. 1996, developed magnetite cationic liposomes (MCL) with 
improved adsorption and accumulation properties. They have a sufficiently high SAR 
and a general biocompatibility that is comparable to that of dextran magnetite (186). 
Since the localization of vesicles in tumour cells can be enhanced by their 
surface charge, Shinkai et al.1996 had also developed MCL with improved 
adsorption and accumulation properties (187). 
MCLs were developed to improve adsorption and accumulation in the tumour 
cells, and show a 10-fold higher affinity for tumour cells than neutrally charged 
magnetolipossomes (188). 
The Kobayashi research group demonstrated the efficacy of hyperthermia by 
using MCL in animals with several types of tumours, such as the B16 mouse 
melanoma (142), T-9 rat glioma (100,189), Os515 hamster osteosarcoma (190), and 
VX-7 squamous cell carcinoma in rabbit tongue (191). 
Ito et al. (192) showed that complete regression of mammary carcinomas of a 
size greater than 15 mm by frequent repeated hyperthermic treatments using MCL 
was obtained in all mice. In these studies, 40– 60% of the injected MCL accumulated 
in the tumour tissue, whereas only 20–25% of the neutral magnetoliposomes 
accumulated. This high accumulation of MCL is considered to be due to the cationic 
charge on the surface of the liposome used. Furthermore, a significant hyperthermic 
effect was achieved. To achieve complete tumour regression, multiple AMF exposure 
is very important. 
However, administration of the MCL is limited to direct injection into the 
tumour tissue (193). 
 
Magnetic metal particles 
Magnetic metal particles mildly induce heat energy in an AMF. Sato et al. 
2008, selected magnesium ferrite (MgFe2O4) as the ferromagnetic metal because it is 
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unreactive in the living human body and provides effective heating (194-197). 
MgFe2O4 particles were formed into a small needle and prepared to safely obtain a 
greater heating effect and target the correct area in the liver tissue. This study shows 
that intrahepatic heating using a new sintered MgFe2O4 stick in an AMF raises the 
temperature of the liver to 60.7 ± 1.1°C. The results of this study, proves that this new 
intrahepatic heating device leads hepatocytes in liver tissue to complete cell death by 
heating at a mild temperature. This device can be considered of value in the future as 
a local heat treatment for human liver cancer. However, the principle for the tumour 
destruction is based on the thermo-ablation, as described above (135). 
 
Bimagnetic Nanoparticles 
The influence of bimagnetic nanoparticles (MNPs) combined with short 
external AMF exposure on the growth of subcutaneous mouse melanomas (B16-F10) 
was evaluated by Balivada et al., 2010 (148). Bimagnetic Fe/Fe3O4 core/shell 
nanoparticles were designed for cancer targeting after intratumoral or intravenous 
administration. Their inorganic center was protected against rapid biocorrosion by 
organic dopamine-oligoethylene glycol ligands. TCPP (4-tetracarboxyphenyl 
porphyrin) units were attached to the dopamine-oligoethylene glycol ligands. Their 
findings indicate that ligand modified nanoparticles given systemically or 
intratumorally at lowconcentrations can significantly attenuate subcutaneous B16-
F10 tumours in mice after repetitive short AMF exposure. Hence, it may be possible 
to exploit upregulated porphyrin uptake by cancer cells to facilitate getting core/shell 
bimagnetic nanoparticles to them. After exposure to an AMF, which itself causes no 
harm, localized hyperthermia of cancer tissue attenuates the tumour without the 
undesirable side effects associated with traditional chemotherapy. This approach also 
circumvents failure of molecularly-targeted approaches due to redundant systems and 
failure of chemotherapeutic approaches due to cancer cell multidrug resistance. 
Furthermore, they surmise that AMF treatment is augmented by the release of iron 
within the tumour regions due to biocorrosion, increasing the intratumoral 
concentration of reactive oxygen species. Thus, localized hyperthermia after systemic 
administration of porphyrin labeled stealth MNPs may hold promise for future 
clinical therapy of melanomas. 
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Needle-type Magnetite 
Ohno et al. 2002, have also improved the method of administration of the 
magnetic particles. The needle-type magnetite consists of magnetite and 
carboxymethyl cellulose and it is as easy to administer as an injection needle. The 
results obtained in this study suggest that administration of the needle-type magnetite 
is a simple and effective method for mediating therapeutic particulate heating in 
hyperthermia treatment (198). 
In two separate studies, Tucker et al. (199, 200) treated rats with two 
hyperthermia treatments using either a resistively heated needle or a single alloy 
thermoseed composed of nickel and copper, both introduced directly into 
subcutaneous Dunning tumours. Intratumoral temperatures maintained for a 2-hr 
treatment were 46.5 and 50ºC, respectively. A significant tumour growth inhibition 
was observed using a matched-pair analysis. 
 
 
MMH combined with other therapies: 
 
Conjugation of antibodies to magnetic particles 
Le et al. 2001 (201) and Shinkai et al. 2001 (163), have developed magnetic 
particles conjugated to the Fab’ fragments of human MN antigen-specific antibody 
and their hyperthermia effects were demonstrated using a mouse renal cell carcinoma 
model. The results indicate that the G250-FMLs (G250 antibody conjugated 
magneto-liposomes) could target the renal cell carcinoma cells in vitro and in vivo, 
and are applicable to the efficient hyperthermia treatment of carcinomas. 
Melanoma antigens are well known and anti-melanoma antibody is available. 
Therefore, “antibody-conjugated magnetoliposomes” (ACMs) using anti-melanoma 
antibody would be expected to be effective for metastatic tumours derived from 
melanoma (146). 
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Gene therapy using magnetic particles  
Ito et al., combined TNF-α gene therapy driven by a heat-inducible promoter 
with hyperthermia produced by the irradiation of MCLs. The combined treatment of 
hyperthermia and gene therapy strongly arrested tumour growth in athymic mice over 
a 30-d period, suggesting great potential for cancer treatment (202, 203). 
 
 
 
Highly Focalized Thermotherapy 
 
A new method for the MMH 
In a previous study, it was assessed a new method of tumour treatment by 
hyperthermia, the Highly Focalized Thermotherapy (HFT). This method consist in 
the direct injection of a material into the tumour and the subsequent exposition to an 
external high frequency magnetic field that will heat the magnetic particles and 
subsequently, the tumour cells. For this purpose, Cavalheiro et al. developed a 
material in the form of an injectable paste (204). Successful in vitro studies were 
performed to assess the biocompatibility of this material, which was later used in vivo 
to treat solid tumours. Treatments were effective in small tumours, with a significant 
reduction of the tumour, but the injection of larger quantities in larger tumours was 
lethal to some animals, because of the material toxicity (205). In an attempt to 
overcome this problem, the same author developed a new material to be used in the 
treatment of tumours using the previously described methodology. The composition 
of this new material, the ferrimagnetic cement (FC), is similar to the silicon–calcium 
cements but with a large amount of ferrimagnetic oxide. 
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2.1 - Materials 
 
Ferrimagnetic Cement (FC) 
The FC is a fine powder (Figure 17), which has a chemical composition in 
weight percent, based on oxides, corresponding to  
10SiO2, 2Al2O3, 52Fe2O3, 0,6MgO, 33CaO, (SO3+K2O) R,  
with a maximum particle size of 5 µm. 
 
 
 
Figure 17 - A) FC powder and distilled water. B) FC paste obtained from the mixture. 
 
 
Control material used in the In vivo Biocompatibility study 
The material used as control, is a low-density polyethylene, in the form of 
rounded samples, with 4 mm diameter and with a smooth surface, which is shown in 
figure 18 (206). 
A	  
B	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Figure 18 - Polyethylene, as a control material, implanted in the rat muscle. 
 
 
Animal model used in the in vivo Biocompatibility study 
To assess the FC biocompatibility, female Wistar rats with 19-21 weeks, were 
used. Animal’s average weight was of 200–230 g. 
 
 
Tumour model for the HFT study - Animal model and tumour cell line  
Inbread female’s C57BL6 mice, with 8-10 weeks old and weighting 20-25g 
were used for the melanoma induction trough the B16F10 cell line subcutaneous 
injection (Figure 19). The melanoma cells line was purchased in ATCC and 
maintained in standard culture conditions, i.e. α-minimal essential medium (α-MEM) 
containing 10% fetal bovine serum, 2.5 µgmL-1 fungizone, penicillin-streptomycin 
(100 IU mL-1 and 2,5 µg mL-1, respectively), and incubated at 37ºC in a humidified 
atmosphere of 5% CO2 in air. 
 
 
 
Figure 19 - B16F10 cell subcutaneous injection, to induce the melanoma mouse tumour. 
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Fifteen days after the tumour induction, the tumour grew in almost all animals, 
but with some differences in their dimensions (Figure 20).  
All experimental animals used in this study were purchased from the 
Laboratory Animal IBMC (Portugal) and maintained in the IPATIMUP vivarium 
under conventional conditions (they had 12 h of light per day and were fed a standard 
laboratory diet and tap water ad libitum) during the course of the experiment. They 
were carried out according to guidelines NP EN ISO 10993-2:2000 (207), taking in to 
account the animals welfare conditions and minimizing the number of laboratory 
animals used in tests (208). 
 
 
Figure 20 - Melanoma mouse model. Measurement of the tumours dimensions. 
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2.2 – Methods 
 
2.2.1 - FC in vitro studies 
 
Injectability 
The injectability of FC was assessed by the ejection of the paste through 
disposable syringes with a G16 needle, following a method that was adapted from the 
method described in the literature (209-211). The injectable cement paste percentage 
was defined as the percentage resulting from the difference between the volume of 
expelled paste and the volume of the paste that was initially in the syringe; thus, the 
injectability percentage was calculated using the following formula: 
 
Injectable % = Volume of paste ejected from the syringe/ 
                        Total volume of paste before ejection 
 
Specific heating power 
After mixing the FC samples with water, small discs of the solid material were 
placed in an isolated polyethylene tube with distilled water and exposed to a magnetic 
field (10 kHz) in a vertical coil (diameter 11 cm, 12 turns), using an induction system 
High Frequency Electronic Furnace K10/RV (CALAMARI and Milan, Italy). The 
variation of temperature was measured after 300 s of exposure to the magnetic field, 
using a digital thermometer. 
The specific heating power (P) was calculated according to the following 
formula: 
 
P = ∑ (Cpi . mi) . Δ T/300 
 
where Cpi and mi are the specific heat capacity and the mass of each material 
(polyethylene, FC, water), respectively. 
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Characterization of the surface morphology and qualitative and semi-
quantitative analysis 
 
Scanning Electron Microscopy / Energy Dispersion Spectroscopy (SEM/EDS) 
The samples were prepared with the FC paste, in accordance with the pre-
established powder/liquid ratio (212), which was placed in a 10 mm diameter and 5 
mm high round mould, thus obtaining regular surfaces for later observation. After the 
material had set (98 min), the samples were removed from the mould. They were then 
divided into 5 groups, according to the different immersion times in a simulated 
physiological environment (SBF), after a preliminary study performed using the 
normal SBF medium during 4 days. A sixth group was created to the measurement of 
the average size of the precipitates.  
The ion concentration of normal SBF, the synthetic plasma generally used in 
this kind of test, is similar to that of blood plasma (213). In this study, after the 
preliminary evaluation using normal SBF, the calcium (Ca) that exists in natural 
plasma was replaced by strontium (Sr) to prepare the SBF Sr solution, thus enabling 
the identification of the source of the occasional precipitates that occur on the surface 
when the FC samples are immersed in this environment, without confusing the Ca of 
FC with that of the solution. Samples were immersed in SBF Sr at 37ºC, for 1, 6, 10, 
24, and 43 h, respectively. The control samples were not immersed. After the 
immersion period the samples were placed on carbon conductive tape in order to be 
observed and characterized using SEM and EDS. The surface of the FC sample, 
which is insulated, becomes conductive, due to the cathode deposit of a carbon film 
(214, 215). 
The morphological analysis of the samples surface was performed using the 
SEM JEOL JSM-6301 (Joel Ltd, Japan) with an accelerating voltage of 15 kV and a 
working distance of 15 mm, at different magnifications (200x, 1000x, 2000x). It was 
also carried out an observation on retro-diffused electrons, locating the elements of 
high atomic number (Sr, Fe) which, through this method, stand out in the image. 
Calcium, silicon, phosphorus, iron, magnesium, strontium, and carbon elements were 
accessed through qualitative and semi-quantitative microanalysis of the surface by 
EDS, using a Voyager system (Noran Instruments, Inc, USA). 
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X-ray diffraction 
X-ray diffraction (XRD) analysis of FC samples control, prepared as described 
above, and FC samples immersed in SBF Sr for 7 days, was performed by a X’Pert 
Philips diffractometer, using CuK_1 radiation, Generator Settings: 50 mA, 40 kV 
with identification software PANalytical. The start position was (º2Th.) 3,5221 and 
the end position (º2Th.) 106,4421. 
 
Measurement of the average size of the precipitates 
Samples immersed for 10 and 24 h in SBF Sr were broke up to observe their 
cross-section, approximately perpendicular to the surface, viewing the crystals and 
enabling their measurement from the initial surface, to determine the average size of 
the precipitates formed. The variable studied is a continuous quantitative variable 
(216), and the average and standard deviations of each of the samples obtained were 
ascertained. 
 
 
2.2.2 – In vivo biocompatibility study 
In order to assess the biocompatibility of FC, samples of this material and a 
control material were implanted in nine female Wistar rats. Animals were 
anesthetized with a combination of Ketamine (80–100 mg/kg) and Xylazine (5–10 
mg/kg) by intraperitoneal injection (217). 
The surgery consisted in the implantation of FC samples in the muscles on the 
left-hand side of the animal’s flank, while the control, was implanted into the flank 
muscles on the right-hand side. Short-term tests were performed at 1, 3, and 9 weeks. 
 
Histological analysis 
Animals were euthanized using an overdose of intraperitoneal pentobarbital, 
and the implanted material was removed along with the adjacent tissues. The 
collected samples were immersed-fixed in 10% (v/v) formalin in 0.1 M phosphate 
buffer (pH = 7.4), embedded in paraffin, sectioned into slices of 5 µm thickness and 
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then stained with haematoxylin and eosin. To assess the tissue response to the 
material, the fixed samples were observed under a LEICA Optical Microscope 
(LEICA DMLB, Q 500 IW) equipped with a photographic system that enables 
snapshots performed at microscopic observation of the samples. The biological 
response parameters were assessed and recorded according to ISO 10993-6:1994 
(218), on the basis of:  
(a) The extension of the fibrosis or fibrous capsule and inflammation response; 
(b) The degeneration ascertained through alterations in the tissue morphology; 
(c) The number and distribution, according to the distance between 
material/tissue, of types of inflammatory cells, namely polymorphic-nuclear 
leucocytes, lymphocytes, plasma cells, eosinophil, macrophages and multinucleate 
giant cells; 
(d) The existence of necrosis, determined by the presence of nucleus remnants 
and/or capillary wall collapse; 
(e) Other parameters, such as remnants of the material, fat infiltration and 
chronic granulomatous inflammation. 
 
 
2.2.3 – Highly Focalized Thermotherapy treatment planning  
 
Tumour induction  
The experimental tumours were induced by subcutaneous inoculation of 
melanoma cells (2 x 105 cells/80µl in cell culture medium) in the animals dorsal 
lumbosacral region. Tumours grew freely until they reached approximately 10mm in 
diameter (corresponding to 523mm3 in volume). 
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HFT treatment methodology 
Animals, with the induced tumours, were divided in three groups, two control 
groups and a treatment group: 
- Control group I (n=5), tumours growth freely without any treatment.  
- Control group II (n=5), animals were injected with FC, without being exposed 
to HFMF.  
- Treatment group III (n=10), the animals were injected with FC and then, 48h 
latter, exposed to the HFMF (frequency 10 kHz) created by a vertical coil (diameter 
110 mm, 12 turns), using the induction system High Frequency Electronic Furnace 
K10/RV (CALAMARI and Milan, Italy). 
Animals were anesthetized before the experiments with a Ketamina, Xilazina 
and distilled water solution (217). The treatment consisted in three expositions of the 
animal model to HFMF, each one during 30 minutes, with 48 hours interval. 
 
FC distribution within the tumour 
FC was directly injected into the animal’s tumour of the control group II and 
treatment group. The FC distribution within the tumour was assessed by radiography 
(Trophy CCX Digital-computer controlled X-Ray). 
 
Temperature monitoring 
The animal body temperature was monitored through a thermal camera, FLIR 
A325, and analysed using the software ThermaCAM TM Researcher Professional 2.9. 
Through the infrared thermography the skin temperature can be assessed remotely 
from the amount of heat that it radiates in the infrared spectrum (219). The emissivity 
value chosen for the present study was 0,98, the same of the human skin (220). 
The control of the HFMF strength was manually adjusted, so that the desired 
temperature of the tumour was kept constant. To allow a more accurate body 
temperature measurement using thermography, the fur that covers the animal’s body, 
was removed in the tumours area. The camera colour pallet range was set from 19.5 
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to 43 ºC, and the area to be evaluated, defined as a circle within the software, logged 
the maximum value. 
 
Tumour growth 
After FC injection, the tumour growth of each mouse was monitored every 2 
days, by two-dimensional measurements (length and width) of individual tumours. 
These measurements were recorded during all the experiment period, until the 
animals sacrifice, enabling the evaluation of the tumours volume change.  
Tumour volume (mm3) was calculated by the following formula (221): 
Volume = (π/6) x tumour length x (tumour width)2 
 
Statistical analyses were performed to evaluate the time course of tumour 
growth along the HFT treatment between the study groups. The statistical test used to 
perform the data analysis was the ANOVA Repeated Measures with post-hoc 
Bonferroni test (whose purpose was to see if there were differences in values found in 
control and treatment groups on the various measurements). In order to apply this 
parametric strategy, the requirements of normality (the Shapiro-Wilk test – p>0,05), 
homogeneity of variances  (the Levene Test – p>0,05) and sphericity (the Mauchy’s 
test with the Greenhouse-Geisser correction – p>0,05) were first verified. All the 
tumour volumes data were represented as mean +/- standard error (SE). 
 
FC biological behaviour within the tumour and iron measurements 
For the FC biological behaviour analysis and iron measurements, three animals 
of the treatment group were euthanized at the end of the experiment and their spleen, 
liver, lung and tumour were collected and snap frozen. 
The FC surface, removed from the tumour, was analysed under Scanning 
Electron Microscopy of high resolution FEG_ESEM (Schottky) with X-Ray micro 
analysis (SEM/EDS in an atmospheric equipment - FEI Quanta 400FEG ESEM / 
EDAX Genesis X4M - CEMUP, Portugal), enabling samples to be directly observed. 
Staining for iron content was carried out by using Perl’s Prussian blue staining (222).  
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Histological analyses 
In order to assess the effectiveness of the HFT treatments through the analysis 
of cells response, animals were euthanized at different periods of time, 4, 24, and48 
hours after the last treatment and the respective tumours removed. The collected 
samples were fixed in 10% buffered formalin and paraffin-embedded. Two 
consecutive sections, 2 µm thick, were made, one being stained by haematoxylin and 
eosin (HE) for histopathologic evaluation and other for the immunohistochemical 
study. Both were independently examined by two pathologists (IA and FG). When 
there was a divergence of opinion, an agreed diagnosis was reached by using a 
multihead microscope. 
For the immunohistochemical (IHC) study, antigen retrieval was performed on 
deparaffinised sections by boiling in a steamer in 10 mmol/L sodium citrate buffer, 
pH 6.0 for 3 min. Slices were allowed to cool for 10 min at room temperature and 
rinsed twice in triphosphate buffered saline (TBS) for 5 min. After blocking 
endogenous peroxidase with hydrogen peroxide 3% in methanol for 10 min, sections 
were subjected to immunohistochemical staining with a policlonal antiserum against 
cleaved Caspase-3 (Asp175, Cell Signaling Technology, Inc., USA), diluted 1:100, 
overnight at 4 ºC, and visualised with the NovolinkTM Max-Polymer detection system 
(Novocastra). Sections were rinsed with TBS between each step of the procedure. 
Colour was developed using AEC Chromogen (DakoCytomation) and sections were 
then lightly counterstained with haematoxylin, and mounted using an aqueous 
medium. Negative controls were included in which the primary antibody was omitted 
and replaced by TBS. 
To access immunoreactivity of Caspase-3 (apoptosis marker), selected tumour 
sections were analysed, being appreciated the formation of a red-brown product of 
reaction at the place of the target antigen, regardless of its intensity. Areas of necrosis 
or inflammatory cell infiltration were avoided. Scored was evaluated by visual 
assessment of the number of positive cells in ten randomly high power (400x) fields 
of magnification, with help of a microscope guide. The percentage of positively 
stained cells in the total cellular neoplastic population was taken as the 
immunohistochemical index. 
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3.1 - FC in vitro studies 
 
Injectability 
A correlation between the injectability and the setting time for the 
powder/water ratio used was previously determined according to ISO 9917:1:2003 
(223). When a higher powder/water proportion was used, the material, immediately 
after being mixed, revealed a significant increase in viscosity, preventing its 
injectability. Needle diameter also affects its injectability, since the cement does not 
flow through a diameter smaller than 1.6mm (G16) (Figure 21). 
For the determined powder/water combination ratio and with firm pressure 
(equivalent to 1kg strength), an injectability value corresponding to 90 ± 1% of the 
total FC paste volume was obtained, during the 5 minutes after the mixture. 
 
 
Figure 21 - FC paste flowing from a G16 needle. 
 
 
Specific heating power 
FC, when exposed to a magnetic field can effectively produce heat. Its specific 
heating power (P) was determined according to the FC mass, magnetic field intensity 
and exposition time. The system created for the FC specific heating power 
determination, provided a maximum heating power of 2.11 W g-1. 
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Characterization of the surface morphology and qualitative and semi-
quantitative analysis 
 
Scanning Electron Microscopy/Energy Dispersion Spectroscopy - SEM/EDS 
The results obtained through SEM and EDS of the FC surface samples were 
divided in 5 groups. Each group includes surface morphology images taken by SEM 
and graphs illustrating the composition variation obtained using EDS analysis.  
The initial cement surface of the control samples, not immersed in SBF (Group 
I), was analyzed with SEM, for the morphological evaluation. The control surface 
presents a very porous surface with larger (6-7µm) and smaller pores (2-3µm). The 
calcium silicates and magnetite compounds are detected in the EDS analysis, where 
iron (Fe), Calcium (Ca) and silicon (Si) are dominant (Group I-D). 
Samples were immersed in normal SBF for 4 days (Group II), and it was 
observed the formation of precipitates over the initial surface. It was detected he 
precipitation  of Ca and magnesium (Mg) phosphate  compounds, a high peak of 
phosporus (P) was identified and all of the initial cement peaks of Si  and Fe 
decreased (Group II-B). 
In the SBF Sr samples immersion for 1 hour (Group III) a decrease in porosity 
can be observed when compared with the control samples. This decrease in porosity 
is due to the formation of precipitates over the initial surface. The spectrum analysis 
detected the presence of Sr and a decrease in Si (Group III-C). In Group II, the Ca 
present in the surface can be from FC or from the SBF. In the groups immersed in 
SBF Sr, the Ca came from FC, since in the SBF Sr, the Ca was replaced by Sr. 
Samples immersed for 6 hours (Group IV) have just small pores and an 
increasing formation of precipitates covering the surface. On EDS spectra of this 
layer we can observe the peaks of Ca, Mg, Sr and also carbon (C) (Group IV-C). 
Over 43 hours of immersion (Group V) the initial FC surface is completely covered. 
The initial composition of the FC (manly Fe and Si) is not detected (Group V-C). The 
higher percentage of Sr results from the increased precipitation of the SBF Sr 
solution. 
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Group I – FC control samples after cement preparation (SEM). (A) At 200x magnification, a very 
porous surface is observed. (B) The same image at a higher magnification (1000x), the FC particles 
can be identified. (C) In the retro-diffused electron image, shiny, lighter and larger particles 
corresponding to Fe, the high atomic number element (arrows).  
Results 	  
	  72	  
 
Group I-D - FC control samples after cement preparation (EDS). Initial surface spectrum, where peaks 
of Fe, Ca and Si can be seen, as well as small percentages of Aluminium (Al) and Mg, which are 
components of FC. 
 
 
 
Group II – FC samples immersed in normal SBF (EDS). (A) Precipitates covering the initial surface 
(1500x magnification). 
Results 
	   73	  
 
Group II-B - FC samples immersed in normal SBF (EDS). The precipitation  of Ca and Mg phosphate  
compounds is detected. All the initial cement peaks of Si  and Fe decreased and a high peak of P can 
be observed.  
 
 
 
 
Group III – FC samples immersed for 1 hour in SBF Sr (EDS). (A) There is a general decrease in 
porosity, with 3-4µm pores and smaller 1-2µm pores, observed at 200x magnification. 
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Group III – FC samples immersed for 1 hour in SBF Sr. (B) SEM image at higher magnification 
(2000x) reveals, besides the pores, the formation of crystalline precipitates on the surface (arrows). (C) 
EDS surface spectrum displaying Ca, Fe and smaller percentages of Si, Mg, Al, and the initial 
presence of Sr. The particles containing Fe and Si start to become covered with precipitates rich in Ca 
and Mg. 
Results 
	   75	  
 
 
 
 
 
 
Group IV - FC samples immersed for 6 hours in SBF Sr (SEM). (A) At 200x magnification, only small 
pores are visible, along with the increasing formation of precipitates that cover the initial FC surface. 
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Group IV - FC samples immersed for 6 hours in SBF Sr. (B) SEM image at magnification x1000. (C) 
EDS spectrum of the surface that is composed of Ca, Mg, Sr and C, displaying the precipitates, which 
are coating it. The initial surface, marked by Fe, is almost totally covered. 
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Group V - FC samples immersed for 43 hours in SBF Sr (SEM). (A) The initial FC surface is 
completely covered with precipitates, at 200x magnification. (B) A precipitate at x2000 magnification. 
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Group V - FC samples immersed for 43 hours in SBF Sr. (C) - EDS spectrum of the sample surface 
that is covered with Ca, Sr, Mg, C and P, resulting from interaction with the synthetic plasma. 
 
 
 
 
 
X-Ray diffraction - XRD 
Rx diffraction of FC control samples allow the identification of picks of the two 
major compounds of the cement: magnetite (2θ=35.48; 62.56), corresponding to 
d(Aº) 2.530, 1.484 and calcium silicate Ca3SiO5 (2θ=29.46; 32.26; 34.40) 
corresponding to d(Aº) 3.031, 2.775 and 2.607 respectively. After immersion in SBF 
Sr, the FC surface is covered with large crystalline precipitates of strontium 
carbonate. The main picks belong to SrCO3 (2 θ=25.42; 25.84; 36.64) corresponding 
respectively to d(Aº) 3.503, 3.448 and 2.452. These results can be observed in Graph 
II. 
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Graph II – X-ray diffraction patterns of control samples (A) allow the identification of peaks of the two 
major compounds of the cement: magnetite (2θ=35.48; 62.56) and calcium silicate Ca3SiO5 (2θ=29.46; 
32.26; 34.40). In the samples immersed 8 days in SBF Sr (B) the surface is covered with large 
crystalline precipitates. The main peaks belong to crystalline SrCO3 (2θ=25.42; 25.84; 36.64). 
 
 
 
 
Measurement of the average size of the precipitates 
Images taken after the FC samples broken up, displaying their cross-section, are 
presented in Group VI. The measurement of the average crystal size, in accordance 
with the corresponding scale displayed in the image, provided the results shown in 
Graph III. The final average of the measurement of precipitates of the 3 surfaces 
immersed for 10 hours in SBF Sr is 8.4µm, corresponding to a development of 0.8µm 
per hour. After 24h of immersion, the precipitates have an average size of 24µm, 
implying that there has been an average development of 15.6µm (24µm- 8.4µm) over 
the 14-hour period (10h-24h), corresponding to an average growing rate of 1.1µm per 
hour. It was observed that the growth orientation of the precipitates occurs from the 
initial surface. 
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Group VI – Measurement of the average size of the precipitates (SEM). (A) Broken up FC samples, 
after having been immersed for 10 hours (2000x magnification). (B) Broken up FC samples, after 
having been immersed for 24 hours (2000x magnification). 
 
 
 
 
Group VI-Graph III – Measurement of the average size of the precipitates in the FC samples, 10 and 
24h ours after immersion in SBF Sr. 
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3.2 - In vivo biocompatibility study 
The results obtained from histological observation one week after the 
implantation of the control material (Group VII) and of FC samples (Group VIII) 
reveal an inflammatory infiltrate surrounding both materials, although the extent of 
this infiltrate and some of the cells that compose it are somewhat different. 
The histological data regarding the samples obtained are compatible with a 
chronic inflammatory process in the control material samples and with a chronic 
foreign-body granulomatous inflammatory process in the FC samples. 
Comparing the images correspondents to 3 and 9 weeks of the control material 
implantation (Group VII B and C) reveal that the layer of inflammatory cells 
surrounding the cystic lesion is thinner and has less inflammatory cells. The 
macrophages present in the images taken 3 weeks after the implantation are not 
visible in those taken after 9 weeks and the number of lymphocytes has significantly 
decreased. 
FC samples also show a clear decrease in the inflammatory infiltrate throughout 
the implantation period (Group VIII A, B, C). Foreign-body reactive multinucleate 
giant cells were observed, in addition to other inflammatory cells. After 9 weeks the 
FC could be seen surrounded by muscle tissue with a thin layer of inflammatory cells. 
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Group VII – Implantation of the control material (50x magnification). (A) One week after 
intramuscular implantation of the control material. An inflammatory infiltrate is observed between the 
muscle tissue and the control material. The inflammatory cells are lymphocytes, macrophages and 
mastocytes, also present in the muscle tissue. (B) Three weeks after implantation. These reveal an 
empty cystic lesion, corresponding to the control material implantation area and a thin layer of 
inflammatory cells limited to its peripheral area, without any significant infiltration of the adjacent 
muscle tissue. The inflammatory cells of the layer surrounding the cystic lesion are mostly 
lymphocytes and macrophages. 
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Group VII – Implantation of the control material (50x magnification). (C) Nine weeks after 
implantation. These reveal that the cystic lesion that was observed at the end of three weeks of 
implantation still exists in the area of the control material. The presence of a few lymphocytes in the 
thin layer of inflammatory cells can be observed. 
 
 
 
 
Group VIII – Images of the intramuscular FC implantation area (50x magnification). (A) After one 
week it is possible to see the nodular inflammatory lesion mainly composed of lymphocytes, some 
plasma cells, macrophages and multinucleate giant cells surrounding the FC (black- stained material). 
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Group VIII – Images of the intramuscular FC implantation area (50x magnification). (B). Three weeks 
after implantation. These display muscle tissue and, surrounding the cement, connective tissue and an 
inflammatory infiltrate. The inflammatory tissue that surrounds the cement is composed of a large 
amount of vascularized connective tissue and inflammatory infiltrate, mostly composed of 
macrophages, lymphocytes and foreign-body reactive multinucleate giant cells. (C) After nine weeks. 
The FC is surrounded by muscle tissue in the lower portion of the sample and by an inflammatory 
infiltrate in the upper portion. The layer of inflammatory cells is clearly thinner than the layer observed 
after three weeks of implantation. Consequently, the number of inflammatory cells has also decreased, 
displaying only a few macrophages and lymphocytes. 
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3.3 - In vivo Highly Focalized Thermotherapy study 
 
 
FC distribution within the tumour 
Through the animal’s radiographic image is possible to determine the FC 
distribution within the tumour. It is desired the FC localization centred in the tumour 
to a uniform dissipation of heat along the entire tumour (Figure 22).  
 
 
   
 
   
Figure 22 - Radiographic images of animal’s tumour after FC injection. The FC radiopacity allows its 
localization.  
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FC biological behaviour within the tumour and iron measurements  
The FC morphology (SEM) and the qualitative and semi-quantitative 
composition (EDS), after injection within the tumour, were assessed. In the SEM 
image its possible to identify the injected FC (Z7 and Z8) because of the iron 
particles shiner, and the surrounding environment, namely the involving layer (Z6) 
(Figure 23, 400x magnification). In figure 24, a higher magnification image (1000x) 
was obtained to more accurately define and characterize that layer. 
  
 
 
Figure 23 - Morphological analysis of a FC sample, injected within the tumour, obtained by SEM 
(400x). Z7 and Z8 refers to the injected FC and Z6, to the layer involving FC. 
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Figure 24 - Morphological analysis of a FC sample, injected within the tumour, obtained by SEM 
(1000x). Z8 refers to the sample surface and Z9 the sample inside. 
 
 
The EDS analysis shows that the FC surface composition is different than the 
FC inside, due to the formation of the Ca precipitates layer, as a result of its 
interaction with the surrounding environment. Graph IV, Z7 and Z8 (referent to 
figure 23), and Graph V (referent to figure 24, area Z9), are very similar, confirming 
the FC composition, manly Ca, Fe and Si. Graph VI (referent to figure 23, area Z6) 
and VII (referent to figure 24, area Z8) refers to the layer involving FC. Peaks of Ca, 
P and C and a significant decrease in Fe and Si, are detected when compared to the 
FC inside. The FC original surface was encapsulated by bone like inorganic 
compounds confirming the in vitro FC biological behaviour studies. 
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Graph IV - EDS analysis of FC inject referent to figure 23, Z7 and Z8 areas. Peaks of Fe, Ca and Si are 
detected and other elements such as Al and Mg in lower quantities. 
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Graph V - EDS analysis of the injected FC sample referent to figure 24. The inside (Z9) is composed 
by Ca, Fe, Si, Mg associated to P and C. 
 
Graph VI - EDS analysis of the injected FC sample referent to figure 23, from the layer involving FC 
(Z6 area). Peaks of Ca, P and C are detected and the Fe and Si content decreased. 
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Graph VII - EDS analysis of the injected FC sample referent to figure 24. The surface (Z8) is 
composed of Ca associated with P and a high peak of C. 
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The assessment of iron content in crucial organs like lungs and liver was 
negative using the Perls staining (Figure 25). In the spleen, there were detected some 
iron traces considered as a normal occurrence, since it is a highly vascular organ in 
which the iron from the hemoglobin of phagocytized erythrocytes is currently 
converted to hemosiderin for storage (224). 
 
 
   
   
Figure 25 - Perls staining of spleen (A), liver (B), lung (C) and tumour (D) of the treatment group 
animals. The iron content (blue attaining) was detected in the spleen and in the tumour, near to FC 
(Original magnification 100x). 
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Temperature monitoring 
The HFT application in the melanoma mouse model resulted in a temperature 
increase in the tumour. It was observed, through the thermographic image that the 
initial tumour temperature varies between 30 and 35ºC and the animal’s body 
temperature showed values between 27 and 31ºC, depending on the animal (Figures 
26A and 27A).  
It is important to note that the animal all body fur was not removed and this 
certainly interferes with temperature lecture, due to the fur isolation of the 
temperature and to the different emissivity, and this is the major explication for the 
temperature discrepancy between the tumour and the animal’s body. However, 
comparing the initial tumour temperature with the tumour treatment temperature, 
there was an increase of 5-6ºC in the first 5-10 minutes, whereas the body 
temperature showed only a limited increase (2-3ºC).  When the desired temperature 
was reached, it was maintained during all the treatment period, by controlling the 
magnetic field intensity (Graph VIII). The temperature increase during the HFMF 
exposition is confirmed in all animals, independent of its initial temperature, as seen 
in figures 26B and 27B.  
It was also evaluated the capacity to increase the initial tumour temperature, 
more than the 6ºC, and it was possible by the augmentation of the HFMF intensity in 
2-3minutes (Figure 27C). It is possible to increase the tumour temperature 9-10ºC 
above the initial temperature. 
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Figure 26 - Animal thermographic image. A) Initial state temperature - before the HFMF exposure. B) 
During the treatment - 30 minutes of exposure to the HFMF. 
A	  
B	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Figure 27 - Animal thermographic image. The software used with the thermographic camera allows the 
determination of defined temperature points (spot) or areas. A) Initial - area 30,7ºC, spot 27,8ºC. B) 
During the treatment - area 36ºC, spot 30,1ºC. 
A	  
B	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Figure 28 - Animal thermographic image. It is possible to increase the tumour temperature through the 
augmentation of the magnetic field intensity. Area 40,1ºC and spot 32,5ºC. 
 
 
 
 
 
Graph VIII - Time/temperature monitoring during the animal’s HFMF exposition. Tumour area and 
the point (spot) in the animal’s body far from the tumour. 
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Tumour growth 
The data obtained from the tumours measurement of the different studied 
groups during the time course, is presented in table 9 and graph IX. Figures 29 and 30 
refer to animals from the control group I, control group II and the treatment group, 
respectively. 
 
 
          Day 
Group 
0 2 4 6 8 10 12 
Control Group I 551,82 681,54 872,08 1195,66 1550,22 2161,84 2893,8 
Control Group II 505,34 604 795,52 1113,44 1637,42 2161,8 3032,16 
Treatment Group 622,17 681,54 806,02 911,22 1049,74 1217,93 1490,89 
Table 9 - Tumours volume average, of all the study groups, in the different measurements days. 
 
 
 
Graph  IX - The time courses of tumour growth. The average tumour volume (mm3) at 2 days 
intervals; the day 0 corresponds to the FC injection within the tumour, in day 2 the measurement was 
realized after the 1º treatment, in the day 4 after the 2º, in the day 6 after the 3º treatment, and in the 
day 12, the final measurement, corresponds to 6 days after the last treatment. Each graph line 
represents the tumour growth in each group. The end of the line indicates the first mouse death. 
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Figure 29 - Control group animal’s tumour. Control group I A - initial; A’- final. Control group II B - 
initial; B’- final. A significant increase in the tumours dimensions can be observed, with the leg 
movement’s limitation. The injected FC had no effect on the tumour development. 
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Figure 30 - Treatment group animal’s tumour before exposure to the HFMF (left images) and at the 
end of the treatment, after the 3 HFMF exposures (right images). The tumour dimensions increased, 
but in a more contained, limited evolution. 
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The results obtained from the tumours measurement were statistically treated 
using the Repeated Measures ANOVA with a Greenhouse-Greisser correction. The 
evolution of tumour growth, among the three groups differed, in a statistically 
significant manner (F(2.488)=155.492, p<0,01) (Table 10). Between the control 
groups I and II, there was no statistically significant difference (p>0,01) but, between 
the control groups and the treatment group there was a statistically significant 
difference (p<0,01). 
 
 
 
 
 
 
Table10  - Significance analyses between the study groups by the post hoc analysis for multiple 
comparisons using the Bonferroni Statistic by the non-parametric ANOVA. The results show a 
statistically significant difference (p<0.1) 
 
 
 
 
 
 
 
 
 
 
 
 
(I) Group (J) Group Sig. 
Control Group II  1,000 
Control Group I 
Treatment Group ,001 
Control Group I 1,000 
Control Group II 
Treatment Group ,000 
Control Group I ,001 
Treatment Group 
Control Group II ,000 
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Histological analyses 
The histological analyses of the tumour samples obtained 24h after the last HFT 
treatment, stained with HE, revealed a proliferation o tumour cells composed of large 
round to polygonal cells that usually form nests, surrounding multiple areas of 
necrosis. The tumour cells presented oval to vesicular nuclei with variable 
pleomorphism, prominent nucleoli and moderate to abundant cytoplasm with highly 
variable degree of pigmentation (brown granular appearance). Two or more mitotic 
figures per high-power (200x) field and some atypical mitotic were observed. It was 
found deposition of an amorphous black material, restricted to the areas of necrosis, 
consistent with the FC (Figure 31).  It was also identified, among viable tumour cells 
and far from the areas of necrosis, many apoptotic figures characterized by extreme 
chromatin condensation, fragmented nuclei with apoptotic bodies, cytoplasm 
shrinking and membrane blebbing. 
In the control group II samples (Figure 32), it was observed the presence of 
tumour cells near to FC, with few inflammatory cells in the transition area and it was 
not detected cells undergoing necrosis. 
Tumour cells response to HFT treatment was analysed after the last treatment, 
at different periods of time (4, 24 and 48h) and compared with the control group II.  
The images obtained from the immunohistochemistry staining for caspase-3 
shows a moderate cytoplasmic immunostaining in most of the tumour cells and strong 
immunostaining in few scattered cells in the treatment group, decreasing along the 
time after the treatment (Figures 33-35). The image on 48h is more like the image 
obtained from the control. The apoptotic activity is greater in the first hours after the 
HFT treatment. The immunohistochemical index (IHC) was determined through the 
histological images. In all the samples, positive immunolabelling was identified, with 
different IHC: 4h - 55%; 24h - 19%; 48h - 14%; control - 6% (Graph X). 
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Figure 31 - Histological image from a tumour of the treatment group, 24 hours after the last HFT 
treatment (HE) 100x and 200x. The upper right corner shows the tumour cells (A), inflammatory 
infiltrate (B) composed mainly of lymphocytes and plasma cells, and areas of necrosis (C). In the 
lower left corner, the FC (D).  
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Figure 32 - Histological image from a tumour of the control group II, 24 hours after the last HFT 
treatment (HE) 100x and 200x. The image’s right site shows the tumour cells (A), some inflammatory 
infiltrate (B) and in the image’s left side, the FC (D). 
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Figure 33 - Immunohistochemistry (IHC) for caspase-3 in a BL6 melanoma xenografted in mice. 
Moderate cytoplasmic immunostaining in most of the tumour cells and strong immunostaining in few 
scattered cells. A - 4 hours after treatment (100x); a bigger magnification of the same image (400x). 
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Figure 34 - Immunohistochemistry (IHC) for caspase-3 in a BL6 melanoma xenografted in mice 
(100x). B- 24 hours after treatment; C- 48 hours after treatment. Strong immunostaining in the first 
hours after the treatment, decreasing along the time, approximating to the pattern image of the control. 
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Figure 35 - Immunohistochemistry (IHC) for caspase-3 in a BL6 melanoma xenografted in mice 
(100x). D- control group. Few immunostaining cells can be observed. 
 
 
 
 
Graph X - Immunohistochemical index determined 4, 24 and 48 after the last HFT treatment and in the 
control group I, at the time correspondent to the 4hours in the treatment group. 
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The application of the biomaterials science, as the study of materials used in 
fields such as biology and medicine, goes through, initially, the characterization of a 
need and then, all the research and technological development is directed toward that 
goal. In this context, the present work was directed to the identification of the need, 
the development of a biomaterial to meet that need and the course of all the 
investigation was based in the biomaterials science through in vitro and in vivo 
experiments. 
Localized hyperthermia is a powerful therapeutic modality in the tumour 
treatment and the aim of the most of the researchers is the localization and restriction 
of heat in the tumour, without damaging the healthy neighbour tissues (2, 4, 76). The 
magnetically mediated hyperthermia (MMH) technique is one of those research lines. 
The use of magnetic materials in the hyperthermia tumour treatment have been 
developed by many researchers with different approaches (4, 146, 192, 194, 225-
227). 
The need of a vehicle to insert the magnetic particles into the tumours, as a way 
of selectively target the tumour cells, its related toxicity, and its application in the 
tumour treatment by hyperthermia, were the key questions for the present 
investigation. 
There are many approaches to find the more effective vehicle to place the 
magnetic particle into the tumour, such as intravascular infusion (225, 227), magnetic 
fluids (170, 171, 174), magnetite cationic liposomes (186, 189), needle-type 
magnetite (194, 198), thermosensitive ferromagnetic particles injected in phosphate-
buffered saline (147) and bioactive materials as the ferromagnetic cement (FC) (212, 
228), ferromagnetic ceramics (229, 230), calcium zinc iron silicon oxide composite 
(231) and PMMA-based bone cements (232). 
The highly focalized thermotherapy (HFT) was developed in the field of the 
MMH, and FC was developed to be used with this methodology, to transport the 
magnetic particles into the tumour. FC will be injected into the tumour and it is 
desired that its structure will stabilize in the tumours environment. 
The use of an injectable self-setting biomaterial depends on its injectability 
properties, setting reaction and setting time. However, there is no common procedure 
to measure injectability in relation to the setting time (223, 233). The cement (FC) 
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studied in this work is composed of several elements that make up the solid phase and 
uses water as the liquid phase, forming a paste when the two phases are mixed 
together. The microstructure of this paste undergoes continuous transformation from 
the liquid phase to the solid phase. In this process the properties alteration of the 
cementing materials from viscous to viscouselastic is the key to its injectability (233, 
235). The paste should be injected within a short working time, when viscosity is 
high. The determined FC powder/water ratio is easy to mix. The paste obtained 
enabled the injection of a substantial percentage of the sample (90±1%), which can be 
handled within a reasonable period of time (5 minutes) and with an adequate setting 
time. 
Since FC will be used in the treatment of solid tumours by the HFT 
methodology, it’s crucial that the FC has the capability to generate heat when 
exposed to a magnetic field. The in vitro evaluation of the specific heating power of 
FC, demonstrate a temperature increase in the FC sample environment (maximum 
heating power 2.11 W g-1). 
The comprehensive characterization of a material involves the study of a set of 
physical and chemical properties, as well as its microstructure. Detailed images were 
obtained using SEM and a rapid analysis of the chemical composition of small 
portions of the samples was made through EDS and XRD. In vitro studies involving 
the immersion of a material sample in a simulated physiological environment (SBF) 
are often used to assess bioactivity mechanisms, ascertaining the apparent 
biocompatibility of that material (213, 235). The examination of apatite formation on 
a material immersed in SBF is a commonly accepted method to predict the in vivo 
bone bioactivity of a specific material (236).  
The results observed in Group II, after immersion during 4 days in normal SBF, 
show a surface completely covered with precipitates rich in calcium and phosphate 
allowing the conclusion that the FC exhibits a high bioactive behaviour. 
When examining the images of the FC surface characterized by SEM and EDS, 
before and after immersion in SBF Sr for 1, 6 and 43hours respectively, significant 
alterations were detected in the samples morphology and composition over the 
immersion time. Along this period, the porous surface observed in the control 
samples (Group I) was covered by a layer of precipitates, and the final images (43 
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hour immersion-Group V) revealed the continuous formation of precipitates 
emerging from those formed on the previous surface. The measurement of the 
average size of the crystals (Group VI), confirms the continuous formation of 
precipitates, with a progressive increase in the layer thickness (Group VI-Graph III), 
covering the whole original surface.  
The EDS analyses of the surface layer, formed after the SBF Sr immersion, 
shows, initially, peaks of Ca, Si, Fe and Sr, the latter not present in the control 
samples of FC. The Si and Fe percentages decreased very quickly over the immersion 
time. The final surface layer is composed of Ca, Mg and Sr associated to high peaks 
of C and P which after crossing the EDS results with XRD analysis (Graph II) proved 
to be mainly crystalline SrCO2 in association with amorphous calcium compounds. 
Due to the inexistence of Ca in the special SBF Sr medium, the existent Ca of the 
precipitate layer can only comes from the FC. Part of the cement was dissolved and 
the Ca did reprecipitate on the surface. Therefore, there was an ionic exchange 
between the initial cement sample and the surrounding environment. The physical 
structure of a material and the properties of its surface are known to be an indicative 
of a materials biocompatibility (5). The FC samples quickly become coated with 
precipitates, while the initial surface was covered with a layer resulting from 
interaction with the surrounding environment. These precipitates, when immersed in 
normal SBF, had an identical composition to that of the mineral constituents of bone. 
The changes in the compositions of the outer surface of FC, presuppose a bioactive 
behaviour in the organism, similar to other bioactive materials, such as calcium 
phosphate cements (237, 238), bioglasses (239, 240) and silicon-calcium cements 
(28, 241). These materials share the capacity to interact with the surrounding 
environment and to form a layer on their surface that is essentially composed of 
carbonates and phosphates, among other elements present in their composition. Some 
authors report the formation of that layer on the surface of different materials during 
immersion in SBF and describe the bioactive behaviours as an ion exchange 
mechanism between the biomaterial and the physiological solution (242-245). 
In vivo studies are essential for the assessment of medical devices, given that, 
their approval requires that they must be tested on animals before being used in 
humans (246). Although in vitro studies provide information about certain elements 
(the cellular and molecular interaction with biomaterials), they cannot replace in vivo 
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studies, due to the complexity of the biological medium (218, 247). The success 
observed in the integration of biomaterial implants in tissues will depend on the 
capacity to mimic physiological responses, such as repair processes after lesion, and 
to control reactions such as inflammation (218, 248). The mere act of implantation 
reveals the existence of tissue trauma which, in turn, induces a physiological scar 
formation process, consisting of two basic components, inflammation and repair, 
which represent a vast interdependent network, where the mediators of inflammation 
jointly act to trigger and control cellular response (249). Assessment of the in vivo 
biocompatibility of FC was performed by its implantation in an animal model, which 
required a surgical procedure that causes lesions in the surrounding tissues. 
The inflammation, the wound scarring process and the foreign-body responses 
of the organism are generally considered as the tissues physiological response to 
lesions (250, 251). In the present study, the histological data regarding the samples 
obtained 1 week after implantation of the control material are compatible with a 
chronic inflammatory process mainly consisting of lymphocytes and macrophages, 
among other less relevant inflammatory cells surrounding the material. The 
physiological response of inflammation corresponds to a complex series of strictly 
controlled reactions, involving alterations in the expression of genes in blood cells 
(granulocytes, platelets, monocytes, lymphocytes), in inflammatory cells 
(macrophages and mastocytes) and in endothelial cells, especially in the 
microcirculation of the tissues adjacent to the lesion. Although lymphocytes can be 
distinguished on the basis of their specific morphology, the different types of 
lymphocyte cells cannot be identified by conventional microscopy. Besides this, we 
cannot say much about their functional activity (251, 252). However, the number of 
lymphocytes observed in the histological samples is similar in both materials, control 
and FC. Macrophages play a very important role in acute inflammation and probably 
in the biocompatibility of a material. They can release mediators that, in turn, activate 
other cells. It has been established that macrophages also affect the activity of 
fibroblasts and lymphocytes (253). During the first week after the implantation of FC, 
a chronic foreign-body granulomatous inflammatory process was observed. Besides 
the inflammatory cells identified in the control material samples, a few foreign-body 
reactive multinucleate giant cells were found. The presence of foreign-body reactive 
multinucleate giant cells is important because it represents a specific inflammatory 
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response triggered by the foreign substance (254). The giant cells are present in small 
numbers and display their characteristic ring of particle remnants. Depending on the 
size of the implanted materials particles, the organism reacts in a different manner. 
Larger particles cannot undergo phagocytosis, thus remaining inside of the giant 
cells, producing a relatively inert tissue response (254, 255). 3 weeks after the 
implantation, a cystic lesion was observed around the control material, surrounded by 
a fine layer of inflammatory cells, mostly composed of lymphocytes and 
macrophages. The FC samples were very similar to those obtained after 1 week of 
implantation, only displaying a slight decrease in the inflammation around the 
cement, thus reducing the presence of inflammatory cells in the adjacent muscle 
tissue. The images of the implanted samples displayed, after 9 weeks, a significant 
decrease in the inflammatory response. In the control material, the cystic lesion 
surrounding it, was coated with a fine layer of inflammatory cells, where only 
lymphocytes were detected. The FC samples revealed a fine layer of inflammatory 
cells, with lymphocytes and macrophages surrounding part of the cement. Due to the 
absence of giant cells in these images, FC may be considered well tolerated. The most 
significant finding was the presence of cement in direct contact with the muscle 
tissue, displaying no inflammatory infiltrate. There was no necrosis in any of the 
samples, which is normally determined by the presence of nucleus remnants and/or 
capillary wall collapse, fat infiltration or granuloma. If a material is very toxic, it 
induces an acute local response for an indefinite period of time, but that did not occur 
with FC. 
Through the analysis of the in vitro and the in vivo results from the FC 
characterization we can consider it a potential material to be used with the HFT. FC 
can carry the magnetic particles, by injection in the tumour, stay located in the 
injected site, has the capability to generate heat when exposed to a HFMF and can be 
considered a bioactive material, allowing its permanence in the organism for a 
indeterminate period o time. 
Since FC meets those requirements, the next step of the investigation was to 
evaluate the possibility of applying the HFT technique with FC in a melanoma mouse 
model. Additionally, it was also an objective of this study, the evaluation of its 
effectiveness in the tumour treatment, by the study of tumours inhibition and 
destruction. 
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The in vivo experiments in the melanoma mouse model show that FC can be 
injected and remains within the tumour. FC location was determined through 
radiographic image, due to its radiopacity, and its structure stabilise in the tumour 
environment, confirmed by the EDS analysis. The injected FC surface was covered 
by a layer that results from the interaction with the surrounding tumour environment, 
while the FC inside is composed by the main compounds of FC, confirming the 
results obtained in the previous in vitro studies (228). The progressive encapsulation 
of the FC by calcium compounds is important to provide the stability of the material 
in the inside of the body, allowing a repeated treatment without a new injection. The 
repeated exposition is based on Yanase et al studies, which confirm the effectiveness 
of multiple HFMF exposures in attaining tumour regression (189). Those treatments 
should have 48 hours interval to avoid heat shock protein-induced thermoresistance 
(199). 
The FC stays located within the tumour and the poor tumours vascularisation 
can’t carry their compounds to other organs as confirmed in the staining for iron 
compounds. It was not detected the presence of iron in the lungs and liver, and the 
iron trace detected in the spleen doesn’t have significance when compared with the 
amount inside the tumour and can be considered as a normal occurrence, since it is a 
highly vascular organ (224). Instead, by using other ferrimagnetic materials, it was 
found a significant amount of iron in lungs and liver, restricting the HFMF exposure 
to the tumour (147). So, with HFT technique, the animal’s entire body can be 
exposed to the HFMF, preventing unwanted hyperthermia in other tissues. 
In this superficial melanoma model, the animal’s temperature can be monitored 
using a thermographic camera. With this methodology, it is possible to measure the 
temperature variation, simultaneously, in the whole body and in the tumour, during 
the treatment. Since energy deposition in tissues as well as cooling by blood flow are 
difficult to model, a good thermometry control is always needed in clinical practice. 
With the thermographic camera used in this study, it is possible to determine the 
temperature distribution in the tumour, the tumours average temperature, selected 
points in the image field and the temperature evolution along the time, just 
throughout the surface observations. This is essential to control the tumour 
temperature during the treatment period. In some studies it was used an optical 
temperature probe inserted intramuscularly near to the tumour, or within the tumour, 
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near to the injection site of the magnetic particles. The disadvantages are that the 
temperature measured doesn’t correspond to the real tumour temperature, is necessary 
skin opening and the leakage caused in the gelatinous melanoma tumour parenchyma 
increases the variability in tumour volumes (147). The only limitations of the 
thermographic camera, is the tumour location. In the melanoma model and in a 
mammary tumour model (256), superficial tumours, this methodology has a great 
potential as a thermometry control method. In deeper location tumours, is necessary 
to use thermometry probes, which are invasive and give us just a temperature point 
and not the real temperature of the entire tumour. In this context more studies are 
essential even to determine the FC quantity necessary to achieve the desired 
temperature in a particular organ or tissue, depending on its characteristics (81, 91). 
The data obtained show that the initial tumour temperature (33-34 ºC) rapidly 
increased (38-39ºC) and remained constant through the treatment period. In contrast, 
concerning the average of the body temperature, it was observed only a limited 
increase (30 to 32ºC). This indicates that HFT treatment is feasible to heat the tumour 
specifically, with just a slight increase of the temperature in the healthy tissues. 
Tumours temperature was set approximately to 5ºC higher than the initial animals 
temperature; however it was insufficient to completely destroy the malignant 
melanoma, as we have seen in tumour growth evaluation. It’s not possible to make a 
real comparison with other studies because it was the first time that this measurement 
methodology was used. However, at higher temperatures (5 to 7ºC) all the process 
inherent to hyperthermia will be marked. The transient increase in blood flow will 
cause the vascular damage, the decrease in tumour blood flow and the corresponding 
decrease in overall oxygen availability. In consequence of the oxygen decrease, the 
tumour pH will also decrease leading to ischemia and cell death (1). It is important to 
note that HFT allows the application of hyperthermia to specific tumour tissue, and 
that the accurate control of the tumour temperature is possible by manipulating the 
magnetic field intensity. In future experiments we intend to increase the tumour 
temperature in approximately 7-8ºC. Some in vivo studies have used hyperthermia in 
these same melanoma mouse model treatment and the temperature increase varies 
between 5ºC and 10ºC (145, 146, 148, 257, 258)]. In this work, our choice for the 5ºC 
increase was based on the principle of lower temperatures will induce apoptosis and 
minimize the damage to the surrounding healthy tissues but, as in other studies, this 
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temperature was not high enough to completely destroy the malignant melanoma 
(145). 
The time courses evaluation of tumour growth, comparing control and 
treatment groups, demonstrated that HFT inhibits the normal tumour growth. This 
finding can be initially explained by the tumour injection of FC, causing damage in 
the tumour and secondly, by the tumour temperature increasing during the HFMF 
exposure. The tumour growth in the control groups was exponential (with a small 
decrease after the FC injection in the control group II). The experience end was set 
when the first animal died (an animal from the control group I). In the treatment 
group, tumour growth was suppressed after the FC injection and was significantly 
inhibited after the HFMF exposures, comparing with the control groups. However, 
the tumour dimension (10 mm) when HFT treatment started was bigger than the used 
in other studies (5-6 mm) with the same melanoma model treated with hyperthermia 
(145, 146, 226, 257). This might be a reason for the incapability to completely 
destroy the tumour in the present study. 
Many authors, in several fronts, have already validated the feasibility of 
hyperthermia, in the treatment of tumours. However, the molecular mechanism and 
the reason why different heat therapies inhibit tumour growth are not well known. 
The histological analysis obtained in the HFT treatment of the melanoma 
mouse model, is in concordance with the tumour growth inhibition enhanced by cell 
death trough necrosis or apoptosis. Although the temperature needed to induce 
apoptosis or necrosis might vary among cells types, one would expect that higher 
temperatures would result in necrosis. However, it is desirable a tumour destruction 
due to apoptosis, since it leads to few side effects. Necrosis, instead, is characterized 
by rapid cytoplasm swelling and it culminates in rupture of the plasma membrane and 
organelle breakdown as a consequence of extreme physicochemical stress. It can also 
lead to local inflammation due to release of intracellular factors from dead cells, the 
so called damage associated molecular patterns that alert the innate immune system 
(1, 259). In the HE staining, areas of necrosis associated with mixed inflammatory 
infiltrate (neutrophils, lymphocytes and some plasma cells) were identified treatment 
group, near to FC, those cells are surrounded by viable tumour cells. In the control 
group II, the absence of necrotic cells may be explained by its bioactivity observed in 
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the previous biocompatibility in vitro and in vivo studies. So, the presence of necrosis 
was due to the heat created by the FC exposition to the HFMF. 
Apoptosis is defined as a programmed cell death mechanism. Apoptotic cell 
death acts as part of a quality control and repair mechanism by elimination of 
unwanted, genetically damaged, or senescent cells, and as such is critically important 
for the development of organisms (123). The immunohistochemical analysis method 
used for the apoptotic cells identification in this study, was consistent with the 
principle that caspase activation (cleavage of procaspase to active caspase) is a 
hallmark of almost all apoptotic systems (133). Also, caspase 3 is a central effector 
caspase in many cells and mediates the cleavage of itself, other downstream caspases, 
and other caspase substrates. The immunostaining assay revealed a significant 
amount of apoptotic cells in the tumour treatment group, 4h after the last treatment, 
decreasing along the time (4h - 55%; 24h - 19%; 48h - 14%). In comparison, the 
index of the control group was significantly lower than in the animals undergoing 
treatment. Still, the obtained value (6%), may be explained by the apoptosis processes 
that occur spontaneously in almost all neoplasic lesions. The apoptotic activity was 
greater in the first hours after the HFT treatment. These results reinforce the 
methodology used with HFT, of the repeated treatments. In a previous in vitro study, 
it was concluded that many different cell lines are hyperthermia induced apoptosis 
competent, but with varying degrees of sensitivity, and it was defined an apoptotic 
temperature window between 41-45ºC (126). With temperatures above 46ºC, the cell 
death is necrotic. Sakaguchi et al. (1995) (260) have also studied the extent and the 
kinetics of a hyperthermia treatment method in the apoptosis induction in two 
tumours and in normal tissues showing a significant difference between the tumours 
and, meaningfully, between tumour and normal tissues. They concluded that the 
extent and duration of apoptosis seem to be correlated with tumour response to the 
hyperthermia treatment. Another in vitro study was performed to evaluate the effects 
of hyperthermia in the highly metastatic melanoma cell B16F10, the same melanoma 
mouse model used in the present study. Melanoma cells were submitted to one heat 
treatment, 45ºC for 30 minutes. In the first 24hours, cultures showed decreased 
viability and most of the adherent cells were in a process of late apoptosis. However, 
a low but apparently stable percentage of metabolically active cells survived long 
after heat exposure (261). Based on these results, increasing the tumour temperature 
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in 7-8ºC, as purposed for futures investigations, is still possible to undergo apoptosis 
and not only necrose. 
In the present, HFT is one of the several modalities of tumour treatment using 
hyperthermia. In this study, it was verified that HFT as the possibility to successfully 
and selectively heat the tumour tissues, which is the reason why it is expected to 
induce the tumour cell response to hyperthermia, as described in the present study 
Introduction chapter. HFT application and the subsequent results are enhanced by 
means of minimally invasive routes and it is a self-regulated hyperthermia method 
that would allow the resolution of the problem of generating an overheating within 
the irradiated tissues. However, some questions that remain unanswered and new 
questions that can be raised, must be answered, which is why further investigation is 
needed is this field. 
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FC, the cement object of this study, will probably be considered a promising 
material to be used with the described methodology.  
 
The fluid obtained paste has a reasonable working time and can be directly 
injected into the solid tumours. 
 
In a normal or modified simulated body fluid immersion and in the tumours 
biological environment, FC surfaces quickly become coated with a layer of 
precipitates that tends to stabilize.  
 
According to the FC behaviour in the biological environment, it can be 
considered a biocompatible material that can remain in the tumour during an 
undetermined period of time. 
 
FC injected in the tumour, when exposed to a HFMH, has the capability to 
generate heat, which is dissipated through the tumour tissues. 
 
Repeated HFT treatment inhibits, statistically, the normal tumour growth in a 
melanoma mouse model. 
 
 The tumour inhibition seems to be a result of the tumour cell destruction 
enhanced by necrose and apoptose, which is caused by the tumour temperature 
increase. 
 
Taking into account the results of this study, the HFT technique using FC, can 
be considered a minimal invasive technique for the treatment of solid tumours. 
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Despite the HFT therapeutic potential, there are some points that still need to be 
investigated such as: 
 
- the increase of the tumour temperature in order to evaluate de probable 
improvement in the treatment effectiveness; 
- the evaluation of the immunity response mechanism; 
- an approach to the tumour metastasis treatment, based on its mechanism and 
recurrence;  
- the application and impact of HFT  in other solid tumours treatment. 
 
Those lines of investigation should be considered during the course of the HFT 
continuing development. 
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